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Chronic Myeloid Leukaemia (CML) is a clonal Haematopoietic Stem Cells 
(HSC) disorder due to the 9;22 reciprocal chromosomal translocation, which 
results in the generation of BCR/abl “fusion” oncogene and the expression of the 
BCR/ABL oncoprotein, a constitutively-active tyrosine kinase. Chronic-phase CML 
patients are treated with Tyrosine Kinase inhibitors (TKi), such as Imatinib-
Mesylate (IM). However, rather than definitively curing CML, TKi induce a state of 
Minimal Residual Disease (MRD), apparently due to the persistence of Leukaemia 
Stem Cells (LSC). We proposed that the expression of BCR/Abl is suppressed in 
LSC, so that LSC are independent of BCR/Abl signaling and refractory to TKi. This 
suppression is facilitated in the hypoxic environment of stem cell niches where 
HSC as well as LSC reside in bone marrow. Hypoxia-Inducible Factor (HIF) -1α is 
a key regulator of cell adaptation to hypoxia and of HSC and LSC maintenance. 
The aim of this study was to address the in vitro and in vivo effects of the 
pharmacological inhibition of HIF-1α on LSC maintenance.  
We compared three different putative HIF-1α inhibitors, identifying 
Compound X as a very effective inhibitor of CML cell survival and growth in 
hypoxia. Compound X also inhibited the colony-formation ability of primary human 
or murine CML cells. Using our in vitro LSC assay, Culture-Repopulation Ability 
(CRA) assay, we demonstrated that HIF-1α pharmacological inhibition in CML cell 
lines or primary cells incubated in hypoxia suppressed CRA, indicating that 
Compound X suppressed LSC maintenance. This result was confirmed using HIF-
1α shRNA-mediated knockdown. CRA, on the contrary, was not affected by IM 
treatment. 
We tested the effects of the simultaneous combination of Compound X with 
TKi, thinking that such a protocol better approaches a potential clinical setting, to 
exclude antagonist effects of IM with respect to Compound X. We found that, in 
fact, the two drugs had an additive effect as far as the total number of viable cells 
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in hypoxic cultures is concerned. On the other hand, IM did not interfere with the 
detrimental effect of Compound X on LSC maintenance. 
Compound X treatment of BCR/abl-transduced mice decreased the number 
and the percentage of the LSC-containing LSK (lineage–/Sca-1+/c-Kit+) cell 
subset in the BM, without affecting the HSC.  
In conclusion, using two CML cell lines, primary CML cells and a mouse 
model of CML, we demonstrated that IM-resistant LSC are instead sensitive to the 
pharmacological inhibition of HIF-1α. On this basis, we propose the Compound 
X/IM combination as a novel therapeutic approach targeting CML cell bulk as well 




Chronic Myeloid Leukaemia 
Leukaemias are clonal disorders of haematopoiesis where a normal 
haematopoietic cell acquires mutations that confer the capacity for unlimited self-
renewal, enhanced proliferation and impaired differentiation. 
CML is characterized by myeloid hyperplasia of the Bone Marrow (BM) and 
increase of myeloid cells in peripheral blood. The clinical signs often include 
granulocytosis, splenomegaly and enlargement of the liver; nonspecific symptoms, 
such as fatigue and weight loss, may occur; about 40% of patients are 
asymptomatic. In the latter case the diagnosis is driven by an elevated white blood 
cell count [1]. 
The natural history of CML involves three different stages: chronic phase, 
accelerated phase and blast crisis. At diagnosis, 90% of patients are in chronic 
phase, which normally lasts from three to eight years. In this phase, blood cells 
retain a full ability to differentiate. When the disease progresses to the accelerated 
phase, which lasts about a year, myeloid cells, mainly of the neutrophil lineage, 
lose the capacity to differentiate and immature cells (“blasts”) appear in the blood. 
Finally, the disease progresses to the blast crisis, defined by the presence in the 
blood of 30% blasts over the total white blood cell number. During this stage, 
extra-medullary infiltrates of blast are often observed. The survival of patients after 
the onset of blast crisis is reduced to months and even weeks [2].  
CML is characterized by an aberrant chromosomal rearrangement leading to 
the generation of the “Philadelphia chromosome” (Ph). Ph is a shortened 
chromosome 22 originated from the reciprocal translocation between the long 
arms of chromosomes 9 and 22 [t (9; 22)] that causes the addition of 3' segments 
of the proto-oncogene c-abl (9q34) to 5' segments of the BCR (breakpoint cluster 
region) gene (22q11). The translocation gives rise to the BCR/abl fusion gene that 
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transcribes a chimeric mRNA of 8.5 kb. This mRNA is translated into the BCR/Abl 
fusion protein, a constitutively active tyrosine kinase [2]. Ph is found in more than 
95% of CML patients; complex rearrangements that may involve one or more 
chromosomes in addition to 9 and 22 are also present in 5-10% of CML patients 
[3]. The events that favor the translocation are still unclear; however, ionizing 
radiation (IR) is a risk factor for CML and in vitro exposure of haematopoietic cells 
to IR induces BCR/abl fusion transcript [4, 5]. Although Ph was the first 
chromosomal abnormality found consistently associated with a specific type of 
leukaemia, aberrant chromosomal rearrangement are present in other leukaemias; 
e.g., a subset of Acute Myeloid Leukaemia (AML) is characterized by the 
expression of the AML1/ETO fusion protein. 
The human c-abl gene, homologous of the viral v-abl oncogene of Abelson 
murine Leukaemia, encodes for a 145 kDa non-receptor tyrosine kinase 
expressed in particular in haematopoietic cells [6] and neurons [7] and localized 
mainly at the cytoplasmic level [6] (Figure 1). Abl is involved in the regulation of 
the cell cycle, response to genotoxic stress and in integrin-mediated intracellular 
signaling [8]. Under physiological conditions, the Abl tyrosine kinase activity is 
tightly regulated. Deletion or mutation of SH3 (Src-homology) domain activates the 
kinase, indicating that the domain plays a critical role in this process. Several 
proteins are able to bind Abl SH3 domain activating the inhibitory functions [9-11]. 
The fusion of BCR sequence to the Abl SH3 domain, probably, abrogates the 
physiological suppression of kinase activity. Other studies proposed that the SH3 
domain binds the proline-rich (PxxP) region in the center of Abl protein causing a 
conformational change that inhibits the interaction with substrates [12]. 
Figure 1. Structure of ABL protein. Src-homology domains: SH; note three SH domains 
at the NH2 terminus. Proline-rich regions: PxxP bind the SH3 domain inhibiting the kinase 
activity. Nuclear Localization Signal: NLS. Nuclear Export Signal: NES. DNA-Binding 
Domain: DNA BD. Actin-Binding Domain: Actin BD. The Abl isoform 1b, containing a 




The normal human BCR gene encodes for a 160 kDa serine/threonine-
kinase predominantly expressed in hematopoietic cells and neurons (Figure2). It 
localizes mainly at the cytoplasmic level, where it is involved in several signaling 
pathways, especially those regulated by G proteins [13-15].  
In CML, breakpoints within the abl gene occur over a large area at its 5’ end; 
regardless of the exact location of abl the breakpoint, splicing of the primary 
BCR/Abl transcript yields an mRNA molecule in which BCR is fused to abl exon a2 
(Figure3). BCR breakpoints can localize in three different regions; this affects the 
final BCR/abl form. In most CML patients, the break occurs within a 5.8 kb area 
spanning BCR exons 12-16, previously referred to as exons b1-b5, defined as the 
major breakpoint cluster region (M-BCR). An alternative splicing of these 
transcripts leads to the b2a2 or b3a2 junctions. Translation of these mRNAs 
results in the expression of a p210 BCR/Abl chimeric protein, which is present not 
only in most patients with CML, but also in approximately one third of patients with 
Ph-positive Acute Lymphoblastic Leukaemia (ALL). On the other hand, the 
remaining patients whit ALL and rare forms of CML express the p190 BCR/Abl 
isoform. This isoform derives from breaks in the BCR region termed minor 
breakpoint cluster region (m-BCR) which is localized between the exon e2’ and e2. 
The p230 BCR/Abl isoform originates from the third breakpoint cluster region (µ-
BCR) downstream of BCR exon 19. It is associated with the rare Ph-positive 
chronic neutrophilic leukaemia (Figure 3). The transforming principle of the 
BCR/Abl fusion protein is carried by the Abl portion, while the different phenotype 
of the disease is probably determined by the different portion of BCR that 
constitute the fusion protein. The Abl portion of fusion protein is in fact almost 
Figure 2. Structure of BCR protein. Dimerization Domain: DD. Note the Y117 
autophosphorylation site crucial for binding to Grb-2. Rho-Guanidine Exchange Factors 
domain: RHO-GEF. Calcium-dependent lipid binding domain: CaLB. Rac-GTPase-
activating protein domain: RAC-GAP. 
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invariable, while the BCR portion varies greatly. Moreover, the BCR gene can be 
replaced with different genes and still cause leukaemia; e.g., in rare cases of ALL, 
the TEL-abl fusion gene is expressed [16, 17].  
 
 Figure 3. Location of the breakpoints in the ABL and BCR genes. Structures of the 
mRNAs transcribed from various breaks. The arrows indicate the region where the break 
can occur. Minor-breakpoint cluster region: m-bcr. Major breakpoint cluster region: M-bcr. 
 
The expression of BCR/Abl is directly responsible for leukaemogenesis. 
Three major mechanisms are involved in the malignant transformation: altered 
adhesion to stromal cells end extracellular matrix, constitutively-active mitogenic 
signaling and reduced apoptosis [18-20] (Figure 4).  
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To date, chronic-phase CML patients are treated with TKi, first of all IM, 
which specifically target BCR/ABL. However, TKi, despite their impressive efficacy 
as first-line therapy, are unable, in most cases, to prevent the relapse, inducing a 
state of MRD, apparently due to the persistence of LSC. The survival of LSC, in 
fact, is independent of BCR/ABL kinase activity [21-24]. 
Haematopoietic Stem Cells 
Blood cells can be divided in two main groups: lymphoid cells (T, B and 
Natural Killer cells) and myeloid cells (granulocytes, monocytes, erythrocytes and 
megakaryocytes). Haematopoiesis is the process of blood cell formation during 
both the embryonic and adult stage of an organism (Figure 5). In the adult animal, 
all blood cells derive from a small common pool of multipotent HSC [25], that 
rappresent less than 0.01% of the total number of BM cells. In the zebrafish 
embryo, pluripotent HSC arise directly from haemogenic endothelium, lining the 
ventral wall of the Dorsal Aorta (DA). In particular, HSC seem to emerge directly 
from the aortic floor, through a process that does not involve cell division but a 
strong bending. Consequently, a single endothelial cell finds its way out from the 
Figure 4. Signaling pathways activated in BCR/Abl expressing cells. 
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aortic ventral wall into the sub-aortic space, with its concomitant transformation 
into a haematopoietic cell. The process is polarized not only in the dorso-ventral, 
but also in the rostro-caudal versus medio-lateral direction and depends on Runx1 
expression. During this cell transition, called the Endothelial-Haematopoietic 
Transition (EHT), cells express CD41, the earliest marker distinguishing blood 
progenitors from endothelial cells/progenitors. In the mouse, these cells 
(expressing Sca1, c-Kit and CD41) emerge in the lumen of the aorta, budding 
directly from ventral CD31+/CD41- endothelial cells [26-28]. In mammals, the site 
of haematopoiesis changes during the development; during the early embryonal 
development, the sequential sites of haematopoiesis include the yolk sac, an area 
sourrounding the DA termed the Aorta-Gonad Mesonephros (AGM) region, the 
placenta, the foetal liver, thymus and spleen. At 14 to 20 weeks of gestation, HSC 
migrate to the BM, where they are definitively established. The interaction with 
these different environments confers different properties upon HSC: for example, 
HSC are in cycle in foetal liver while are largely quiescent in BM. During the adult 
life, BM is responsible for the generation of all blood cells. In particular, human 
adult haematopoiesis is restricted to the proximal regions of long bones of the 
axial skeleton (cranium, sternum, ribs and vertebrae) in addition to the ilium [29]. 
However, in pathological conditions, such as leukaemia or myelofibrosis HSC can 
re-migrate to sites of foetal haematopoiesis, e.g. liver and spleen.  
Haematopoiesis includes several stages such as commitment to a specific 
cell lineage, increase of proliferation, terminal differentiation of lineage-restricted 
progenitor cells, growth arrest and apoptosis. Such a hierarchical model of 
haematopoiesis has provided a paradigm for the development and regeneration of 
tissues in general as well as for tumorigenesis. All the steps of haematopoiesis are 
highly regulated via the progressive expression or repression of transcription 
factors and cell surface cytokine receptors, driving the interaction of different sub-
populations of haematopoietic cells with the environment (stromal cells, 
extracellular matrix, etc.). 
HSC, like all other Stem Cells (SC), possess the capacity to maintain 
themselves (“self-renewal”) and at the same time to sustain clonal expansion 
generating a rapidly proliferating progeny. HSC self-renewal and concomitant 
clonal expansion are ensured by asymmetric cell division, in which molecular 
determinants of cell fate are redistributed unequally to the two daughter cells, or 
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via environmental asymmetry, in which one daughter cell leaves the “niche” that 
sustains HSC self-renewal and is then exposed to an environment that promotes 
clonal expansion and lineage commitment [30]. In this fashion, only few SC at a 
time move from quiescence to a cycling state, giving rise to rapidly proliferating 
Haematopoietic Progenitors Cells (HPC), which directly sustain the generation of 
maturing blood cells. HPC derive directly from Short-Term Reconstituting (STR) 
HSC, capable to sustain haematopoiesis for only few weeks. STR-HSC in turn 
derive from Long-Term Reconstituting (LTR) HSC. The latter cell subset is the one 
typically involved in quiescence and asymmetric division. 
Leukaemia Stem Cells 
The concept of the existence of a primitive population of cancer cells that 
escape the normal control of self-renewal, resulting in unrestrained clonal 
expansion, led to the formulation of the Cancer Stem Cells (CSC) hypothesis. This 
theory postulates that tumours are maintained from a small minority of stem-like 
Figure 5. Normal Haematopoiesis.  
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cancer cells, which possess sufficient self-renewal capacity to recapitulate the 
entire tumour population. CSC could originate from the neoplastic transformation 
of HSC which physiologically possess the capacity of self-renewal, or from HPC 
which acquire this capacity aberrantly, as a consequence of oncogenic 
transformation (Figure 6). In any case, CSC are responsible for the persistence of 
MRD after successful treatment and for resistance to therapy. 
LSC were the first CSC described, in 1994, by Dick and co-workers, who 
dissociated LSC from the bulk of AML cells. In this work, the authors identified 
LSC within the CD34+/CD38- sub-population as cells able to transmit AML to Non-
Obese Diabetic-Severe Combined Immuno-deficient (NOD-SCID) mice. By 
contrast, CD34+/CD38+ AML cells were found not competent in engrafting NOD-
SCID mice, indicating that leukaemic, like normal, haematopoiesis is hierarchically 
organized and that LSC, like HSC, exhibit peculiar and detectable phenotypes [31-
33]. 
  
Figure 6. The two models for cancer stem cell generation. Oncogenic transformation 
of stem cells or acquisition of self-renewal by transformed progenitor cells; 
correspondence of cancer stem cells to normal phenotypes. 
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The haematopoietic stem cell niche 
The decision between self-renewal and maintenance of stem cell potential or 
massive clonal expansion and loss of this potential largely depends on the 
interaction of HSC with the extracellular environment were HSC reside, the HSC 
“niche” [30, 34]. The concept of the haematopoietic niche was first proposed by 
Schofield, who designed the specific features of a microenvironment that ensures 
HSC maintenance by controlling the balance between self-renewal and clonal 
expansion. The niche environment favors HSC maintenance and quiescence, 
privileging self-renewal over clonal expansion, yet allowing, under controlled 
conditions, the SC to generate proliferating HPC. Leaving the HSC niche, HPC are 
enabled to proliferate and eventually differentiate [35] (Figure 7.). These 
Schofield’s predictions were based on the observation that HSC need to reside in 
the BM to retain their “infinite” stem potential, whereas HSC homing in the spleen 
are more restricted in their capacity to sustain haematopoiesis [35-38]. 




Although the idea of the niche was proposed for HSC, the first SC niches 
were experimentally characterized in Drosophila gonads and in Caenorhabditis 
elegans. Today, SC and their niches have been identified in a number of 
mammalian tissues such as muscle, central nervous system, intestinal epithelium, 
bulge region of the hair follicle, interfollicular epidermis, testis and BM [39, 40].  
HSC niches in BM consist of non-haematopoietic cells including fibroblasts, 
adipocytes and blood vessel cells, as well as nerves. Evidences suggest the 
existence of two types of BM niches: the “osteoblastic niche”, located near the 
endosteum, and the perivascular niche, located in the sinusoidal vasculature. To 
date, the functional differences between these spatially distinct niches have not 
been completely characterized and it is not clear if the osteoblasts and endothelial 
cells represent distinct or overlapping niches, and if separate niches, if the HSC 
occupying the niches are the same or have different properties [41-44]. The 
osteoblastic niche, which is a hypoxic niche, privileges the maintenance of HSC in 
a quiescent state (slow cycling or G0). From this niche, the progeny of LTR-HSC 
(STR-HSC) can move to progressively better oxygenated areas, reaching the 
vascular niche were extensive clonal expansion and differentiation are allowed 
following activation of aerobic metabolism in proliferating cells [45-48]. When the 
supply of mature cells is no longer needed and if the LT-HSC’s stem potential is 
not exhausted, stimuli inducing HSC activation and division are withdrawn and ST-
HSC located in the osteoblastic niche can return to G0 [45]. Quiescence is critical 
to sustain the stem cell compartment. Loss of quiescence, as occurs with p21cip1 
deficiency [49], results in a long-term decrease of stem cell pool and its eventual 
exhaustion, so that the shuttling of HSC between the two types of niches might be 
a key feature of well-balanced haematopoiesis. In this respect, Quesenberry 
proposed the so-called Chiaroscuro model of haematopoiesis based on a flexible 
and reversible transition between the stem and progenitor cell phenotypes [50]. 
Quiescence of HSC is, also, closely associated with the protection of the 
HSC pool from the various stresses induced by myelotoxic insults; quiescent HSC 
are, in fact, resistant to 5-fluorouracil (5-FU)-induced myelosuppression [42]. 
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Endosteal (osteoblastic) niche 
Osteoblasts are bone cells in charge of the secretion of unmineralized bone 
matrix proteins, as well as of the regulation of osteoclast differentiation, and 
usually reside in a layer along the endosteum, at the interface between BM and 
bone [29, 51]. 
Studies of the 1970s indicate that undifferentiated haematopoietic cells 
localize close to the endosteal bone surface, but that differentiated cells move 
toward the central axis of BM.  
The concept of “endosteal” or “osteoblastic” SC niche is supported by 
findings that osteoblasts produce factors that have the ability to regulate 
quiescence and maintenance of HSC, e.g. angiopoietin-1, thrombopoietin, 
osteopontin [41, 42, 52, 53]. Moreover, osteoblasts express the chemokine CXC 
Chemokine Ligand (CXCL)-12, which regulates chemotaxis, homing, and survival 
of HSC and has an important role in the retention of HSC in BM [54]. Many other 
in vitro and in vivo studies demonstrated that osteoblasts play an important role as 
part of the HSC niche. Human osteoblasts have been shown to support HSC in ex 
vivo cultures of primitive haematopoietic cells [55-58]. Using mice conditionally 
deleted of bone morphogenetic protein receptor 1A, Zhang and colleagues 
demonstrated that the ectopic formation of trabecular bone-like area and the 
increase of the number of N-cadherin-positive osteoblasts (SNO cells) correlates 
with an increased HSC number. Moreover, they found label-retaining cells thought 
to be HSC attached to the SNO cells, in association with N-cadherin [59]. In 
another study, Calvi and colleagues examined the effects of the constitutively-
activated parathyroid hormone (PTH)-related peptide receptor (PPR). The PPR 
mice had increased HSC in conjunction with increased trabecular bone. They also 
observed an elevated number of trabecular osteoblasts that expressed the Notch 
ligand Jagged-1, required for the HSC-potentiating effects of the osteoblasts. The 
addition of a γ-secretase inhibitor (which inhibits Notch activation) to stromal cell 
cultures prevented this effect. These results were confirmed using wild-type 
stromal cultures or wild-type mice treated with PTH [41]. Moreover, PTH, 
regulating the size of HSC niche, has therapeutic potential for both HSC 
mobilization and haematopoietic recovery post-transplantation in mouse models 
[41, 60]. However, while the expansion of osteoblasts was demonstrated to 
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increase HSC, their decrease could not be consistently linked to a HSC reduction 
[61, 62]. 
Perivascular niche 
Endothelial cells, lining the interior surface of blood and lymphatic vessels, in 
BM form a barrier between the developing haematopoietic cells and the blood.  
The hypothesis of a “perivascular” SC niche emerged mainly thanks to the 
discovery of the SLAM (Stimulated Lymphocyte-Activating Molecule) family 
antigens (CD150+/CD244-/CD48-/CD41-), marking HCS. Histochemical analyses 
of BM sections showed that the majority of HSC resides in the perivascular niche, 
with only 16% of HSC being in the osteoblastic region [43]. However, whether the 
perivascular zone represents a true niche still requires experimental definition. 
Indeed, it is possible that HSC accumulate around the vessels because it is an 
impedance point in their trafficking into and out of the vasculature. Moreover, to 
date, no modification in endothelial function in vivo has been shown to affect HSC 
other than what might be expected from perturbed trafficking. 
However, developmental changes in haematopoiesis would suggest that 
perivascular sites are likely to serve as niches. Whit the exception of BM, all sites 
where HSC can be isolated from during embryonic development contain 
endothelial cells, which have been thus closely associated with the generation of 
HSC [63-65].  
Additional evidence for the vascular niche was also provided using the GFP 
reporter in the CXCL-12 locus. This study identified cells that secrete high levels of 
CXCL-12, named CAR cells (CXCL-12-Abundant Reticular cells) and interact with 
over 90% of HSC (recognized by either SLAM markers or lin-/cKit+/Sca1+). 
Reticular cells around the sinusoids are an important component of the vascular 
niche [44]. In human BM, these cells constitute the sub-endothelial (adventitial) 
layer of sinusoidal walls, projecting a reticular process that is in close contact with 
HSC. Interestingly, reticular cells are derived from a specific subset of 
mesenchymal cells (CD146+) that produces either reticular or endosteal cells. 
Finally, other in vitro studies demonstrated that endothelial cells derived from 
various tissues support HSC in culture, suggesting their contribution to the 
establishment of vascular niche. 
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Hypoxia and Hypoxia Inducible Factor 
Role of hypoxia in normal haematopoiesis and Leukaemia 
One of most important distinguishing features of the haematopoietic stem cell 
niche, with respect to other districts, is the very low percentage of oxygen; in the 
different areas of BM, the physiological oxygen level correspond to an in vitro 0.1-
5.0% range. This implies that an environment which is hypoxic for the overall BM 
cell population is instead normoxic for the HSC. Hypoxia is a consequence of both 
the intense crowding of proliferating/differentiating BM cells and the peculiar 
vascularization of BM. The steep pO2 gradient in function of cell distance from 
blood vessels accounts for the paradoxical situation that, even in the relatively well 
vascularized regions of haematopoietic tissue, hypoxic areas can be easily 
determined within the cell conglomerates, thus constituting the “hypoxic stem cell 
niches” [66] (Figure 8). Oxygen availability in leukaemic BM is possibly even lower; 
due to the further increase of cell density determined by the unrestrained 
expansion of neoplastic cell clones. 
 
Figure 8. The ischemic core of the hypoxic haematopoietic stem cell niche. 
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Furthermore, the core of the hypoxic HSC niche can be defined as 
“ischemic”. Due to hypoxia, indeed, the glucose consumption rate and glycolysis 
are enhanced (the Pasteur Effect), generating areas where glucose is constantly 
at extremely low levels [45, 67] (Figure 8).  
The hypoxic HSC niche is also an acid environment; low pH, due to the high 
lactate and H+ concentration generated via the enhanced glycolysis, is, in fact, a 
common characteristic of hypoxic regions [68] (Figure 8). 
The importance of the micro-environment, in particular oxygen tension, in 
maintaining HSC and regulating their behavior emerged first from a series of 
studies carried out by our group. Severe hypoxia (1% oxygen in the incubation 
atmosphere) enhances the maintenance of stem cell potential of murine and 
human haematopoietic populations. STR-HSC as well as LTR-HSC are completely 
hypoxia-resistant. Less immature progenitors such as Colony-Forming Cells (CFC) 
are, on the contrary, eliminated in the course of hypoxic incubation. Resistance to 
hypoxia was shown indeed to be the higher, the higher the level of progenitor in 
the haematopoietic hierarchy [37]. Interestingly, oxygen levels around 1% allow 
HSC to cycle, being thereby compatible with HSC self-renewal, also a finding of 
our group [69, 70]. Hypoxia modulates the effects of Reactive Oxygen Species 
(ROS) and cytokines such as Erythropoietin (EPo), Thrombopoietin (TPo), 
InterLeukin-3 (IL-3), Granulocytic Colony-Stimulating Factor (G-CSF) and 
InterLeukin-7 (IL-7). Under these conditions, it is possible to ensure self-renewal 
and thereby to maintain the stem cell compartment while the initial clonal 
expansion is triggered (asymmetric division). In vivo, this situation corresponds to 
the endosteal vascular niche where interaction with CAR cells and activation of 
pathways such as Wnt and Notch sustain the stemness and the self-renewal of 
HSC. In these areas, it is possible to maintain and expand stem cells, while the 
extensive generation of fast-growing progenitors necessary for clonal expansion is 
not allowed. When oxygen decreases to below 0.1%, HSC are maintained but 
become quiescent. Such a low oxygen tension is a typical feature of the endosteal 
osteoblastic niche. Here quiescence is maintained by the interaction of HSC with 
Extra Cellular Matrix (ECM) and by signaling mediated by N-Cadherin, 
Osteopontin, Transforming Growth Factor (TGF) β and Stem Cell Factor (SCF). 
Quiescent HSC are probably to be considered at the highest level of the stem cell 
hierarchy and have been identified as LTR-HSC. This is, as mentioned above, a 
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very small fraction of the CD34+/CD38- cell subset, the firm anchorage of which to 
the niche ensures resistance to a number of haematopoietic stresses [71].  
The high percentage of quiescent HSC in the niche is due to the fact that 
hypoxia induces the expression of cyclin-dependent kinase inhibitor genes, p21cip1, 
p27Kip1 and p57Kip2. It has been shown in our laboratory that in hypoxia (but not in 
normoxia) the potential of generating CFC in vitro (a feature of HSC) of CD34+ 
cells which have undergone one replication cycle is maintained or increased with 
respect to that of undivided cells or of cells which have undergone more than one 
replication cycle [70]. Interestingly, IL-3 increases the number of CD34+ cells that 
divide more than once in hypoxia and thereby decreases the stem cell potential. 
Thus, proliferation of HSC beyond the first cycle, under the effects of factors 
inducing lineage commitment, results in the loss of self-renewal ability. A possible 
conclusion is that the maintenance of stem cell potential requires cycling, but this 
cycling needs to be limited to one cycle after exit from quiescence, and that 
hypoxia enforces cycling limitation, resulting in the maintenance of HSC self-
renewal. Other studies carried out in our laboratory showed that Vascular 
Endothelial Growth Factor (VEGF), a factor which is also directly active on HSC, is 
sufficient alone (i.e. in the absence of other cytokines) to maintain the stem cell 
potential of HSC in hypoxia and that this effect is also antagonized by IL-3. Thus, 
VEGF is capable to sustain survival of HSC in hypoxia directly, and then their 
oxygen-dependent clonal expansion indirectly, by stimulating neoangiogenesis. 
A number of studies carried out in our laboratory showed that, not only HSC, 
but also LSC are able to adapt to severe hypoxia [22, 72-74], as they retain many 
characteristics of HSC. In leukaemia, hypoxia plays the same role as in normal 
haematopoiesis, i.e. the maintenance of SC features combined with the inhibition 
of clonal expansion. 
Hypoxia-selectable LSC subsets are likely to exist within any type of 
leukaemia, including stabilized cells lines [22, 72-74]. In CML, either cell lines or 
CD34+ cells explanted from CML patients, hypoxia-resistant LSC are also 
resistant to IM. This resistance is due to the fact that, in a hypoxic environment, 
BCR/Abl, the molecular target of IM, is suppressed. However, hypoxia-selected 
LSC remain genetically leukemic (BCR/abl-positive), as they re-express BCR/Abl if 
cultures are shifted to growth-permissive conditions (incubation in air). This 
intrinsic resistance of LSC to TKi treatment is defined refractoriness [22, 72-74]. 
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The suppression of BCR/Abl can be explained with the fact that oncogenic growth-
promoting signals antagonize the maintenance of LSC self-renewal. This 
predisposes IM-resistant LSC to long-term homing in hypoxic stem cell niches, 
from where BCR/Abl-driven clonal expansion of LPC can be rescued following 
shift to relatively better-oxygenated areas of BM.  
We addressed the effects of oxygen and glucose shortage on different 
subsets of LSC and LPC within CML cell populations [73]. It was possible to 
identify different hypoxia-resistant cell subsets, exhibiting different phenotypes and 
functional properties. Some of these subsets display features of LSC, others of 
LPC. These leukaemia cell subsets are functionally and metabolically 
characterized and reflect the organization of normal haematopoiesis, where the 
regulatory role of glycolysis and respiration within the stem/progenitor cell 
hierarchy is been characterized [36-38, 75, 76]. Three cell subsets were detected 
by modulating the duration of hypoxia and glucose availability. First: LPC 
metabolically similar to cell bulk, in which BCR/Abl suppression in hypoxia has not 
occurred yet and which are therefore IM-sensitive. Second: LPC/LSC where 
oxygen and glucose shortage has determined suppression of BCR/Abl. Third: LSC 
obtained after selection of CML cells following a long incubation in hypoxia and 
glucose shortage, where BCR/Abl is deeply suppressed. The latter subset is 
characterized by complete refractoriness to IM. It is worth noting that BCR/Abl 
suppression is not determined by hypoxia per se, but rather depends on glucose 
shortage in hypoxia. Glucose availability is therefore to be considered the 
regulator of BCR/Abl expression in hypoxia. These observations directly link LSC 
metabolism to resistance to therapy, suggesting that this resistance is linked to the 
depression of not only aerobic production of energy, but also glycolysis [73] and 
that the environment where LSC home in vivo is, like the normal HSC niche, 
characterized by the shortage of both oxygen and glucose. However, in these 
conditions, LSC are still capable to cycle, although the most recent data indicate 
that the longer is the incubation under oxygen/glucose shortage, the larger the 
proportion of quiescent LSC. On the other hand, BCR/Abl expression, which is 
necessary to drive the expansion of leukaemic population, occurs only under 
growth-permissive metabolic conditions [73]. The rescue of BCR/Abl expression 
likely occurs in vivo in relatively well oxygenated tissue areas, such as the 
vascular niches. Thus, the flexible and reversible stem/progenitor cell phenotype 
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shift described by the Chiaroscuro model [50] may be largely conditioned by the 
environmental “metabolic pressure”. 
Hypoxia can also contribute to LSC and HSC maintenance trough the 
regulation of the expression of signaling molecules, including HIF, as described in 
detail below. 
HIF and their role in cancer 
As described in the previous section, hypoxia is an important hallmark of the 
tumor micro-environment and it is one of the most important factor favoring 
neoplastic progression. In normal as well as cancer cells, adaptation to hypoxia is 
driven by HIF, which regulate the expression of genes involved in many cellular 
processes, including pH regulation, glucose uptake, metabolism, angiogenesis, 
cell proliferation and apoptosis. Likewise, in cancer cells, HIF regulate a number of 
steps of tumorigenesis, including tumor formation and progression, as well as 
response to therapy. 
HIF belong to the PAS (PER-ARNT-SIM) family of basic Helix-Loop-Helix 
(bHLH) transcription factors. Active HIF is a heterodimer, composed of an α and a 
β subunit, which binds DNA in the specific sequence 5′-RCGTG-3′ called Hypoxia 
Response Elements (HRE). There are three isoforms of the alpha subunit: HIF-1α, 
HIF-2α (also known as Endothelial PAS-domain protein 1, EPAS1), and HIF-3α. 
The subunits HIF-2α and HIF-3α, in contrast to HIF-1α, which is ubiquitously 
expressed, have an expression pattern restricted to particular tissues. Regarding 
the beta subunit, two isoforms have been identified: HIF-1β isoform, also known as 
ARNT (Aryl Hydrocarbon Receptor Nuclear Translocator) and HIF-2β (or ARNT2). 
HIF activity is regulated by oxygen tension through the stabilization of the alpha 
subunit. In the presence of oxygen (>7%), HIF-α is extremely unstable, due to its 
hydroxylation, in the Oxygen Dependent Degradation (ODD) domain of the 
protein, by specific prolyl-hydroxylases. Hydroxylation causes interaction with the 
von Hippel-Lindau (vHL) protein, a component of an E3 ubiquitin ligase complex, 
and the consequent HIF ubiquitination and degradation within the 26S 
proteasome. When oxygen levels are lower than 7%, HIF-α is stabilized and 
rapidly translocated to the nucleus, where it binds the HIF-β subunit, which is 
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constitutively expressed (Figure 9). In addition, the HIF-3α subunit seems to have 
a regulatory function in both HIF-1α and HIF-2β expression. 
As described previously, hypoxic and/or ischemic areas are common within 
tumor masses, where HIF is therefore frequently activated. Hypoxia is indeed the 
best-characterized mechanism of HIF activation in tumors and normal tissues. In 
keeping with this, many studies found that the expression of both HIF-1α and HIF-
2α is increased in a variety of human tumors, including bladder, breast, colon, 
glial, hepatocellular, ovarian, pancreatic, prostate and renal tumors. Moreover, an 
increase of HIFα expression correlates with poor prognosis [77]. However, there 
are some significant differences between the functions played by HIF-1α and HIF-
2α. During adaptation to hypoxia, HIF expression depends on both the oxygen 
level and the kinetics of its disappearance. In neuroblastoma cells, HIF-1α is 
activated during the early phase of hypoxia (within the first hour), and remains well 
expressed for 48 hours. Later, HIF-1α decreases while HIF-2α increases. Thus, 
HIF-1α stabilization is primarily an acute response to hypoxia, while to role of HIF-
2α is predominant in prolonged hypoxia [78]. 
Another important finding is that HIFα subunits are often expressed also in 
oxygenated areas of tumors. This is mainly due to genetic alterations of the 
oxygen-sensing pathway which cause HIFα stabilization irrespective of oxygen 
concentration in the environment [79, 80]. Inactivation of vHL in renal carcinomas 
and mutations of the Wnt/β-catenin signaling pathway in colon carcinoma are the 
most common alterations determining HIF-1α stabilization. Another important 
hypoxia-independent mechanism of HIFα activation in tumor cells is mediated by 
the PI3-Kinase (PI3K)/Akt-signaling pathway. A number of mechanisms, including 
growth factor signaling, loss-of-function PTEN mutations, gain-of-function 
mutations of HER2neu or insulin-like growth factor-1 receptors, Ras activation, 
result in increased signaling via the PI3K/AKT pathway, leading to increased 
mTOR activity and HIF-1α expression [81]. In addition, p42/p44 mitogen-activated 
protein kinases, which regulate cell proliferation in response to extracellular growth 
factors, also phosphorylate HIF-1α (and HIF-2α) and activate transcription of HIF 
target genes [82, 83]. Collectively, these results suggest that HIF play a central 
role in tumorigenesis. As described previously, the importance of HIF is due to its 
capacity to activate many important genes involved in pH regulation, like Carbonic 
Anidrase (CA) IX, in angiogenesis, like VEGF, in cell metabolism, like GLUcose 
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Transporter (GLUT) and Lactate De-Hydrogenase (LDH)-A, in cell proliferation, 
like TGF and EPo, and in the metastatic process, like CXCR4, E-Cadherin and 
Lysyl Oxidase (LOX). 
Hypoxia induces first the so-called “glycolytic switch”. Otto Warburg 
discovered in the 1920s that tumors, unlike normal cells, convert glucose to lactate 
(via pyruvate) even in the presence of abundant oxygen, a process termed 
“Warburg effect”. Tumor cells, in order to make enough ATP, increase their rate of 
glycolysis using the HIF-1α pathway to induce the expression of GLUT1, GLUT3 
(enhancement of glucose up-take), LDH-A (restoration of NAD+ via the increased 
conversion of pyruvate to lactate) and Pyruvate Dehydrogenase Kinase (PDK) 1. 
Interestingly, pyruvate itself inhibits HIF-1α degradation. Recent work showed that 
HIF-1α also negatively regulates mitochondrial respiration via the transcriptional 
activation of the c-Myc repressor MXI-1 and the regulation of c-Myc protein 
stability [84]. Finally, HIF-1α blocks the oxidative arm and promotes the non-
oxidative arm of the pentose-phosphate pathway, which converts glycolytic 
intermediates into ribose-5-phosphate, a substrate for nucleotide biosynthesis [85]. 
HIF-2α, on the other hand, promotes fatty acid storage via inhibition of the genes 
of β-oxidation, thereby blocking another important pathway of oxidative 
metabolism. In addition, HIF-2α specifically inhibits ROS production via the 
induction of anti-oxidant enzymes such as SuperOxide Dismutase-2 and Heme-
Oxygenase 1. 
The pathways described above are extremely important in the regulation of 
hypoxia-induced cell proliferation. Hypoxia induces indeed the expression of many 
growth factors capable to increase the proliferation rate of cancer cells, such as 
TGF-β, TGF-α, Platelet-Derived Growth Factor (PDGF) and EPo. HIF-1α primarily 
induces TGF-β and PDGF, while HIF-2α induces primarily TGF-α. Both TGF are 
involved in cancer angiogenesis and proliferation. EPo is also a preferential HIF-
2α target [86, 87]. However, HIF-2α controls cell proliferation mainly through 
modulation of c-Myc activity. In this fashion, HIF-2α regulates the expression of 
genes involved in cell cycle control including cyclin D2 (and D1) and cyclin kinase 
inhibitors p21cip1 and p27kip1 [88]. 
A later effect of hypoxia is the “angiogenic switch”, a multi-step process 
driven by a number of pro-angiogenic factors, of which VEGF-A is the most 
important, expressed in a large number of human tumors. VEGF-A is induced by 
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either HIF-1α or HIF-2α and binds its receptors VEGF-R1 (also called Flt-1, which 
is induced in turn by HIF-1α) and VEGF-R2 (also called Flk-1, induced by HIF-2α). 
HIF-1α also promotes the stabilization of the new blood vessels, inducing the 
expression of angiopoietin-1 and -2 and their receptor Tie-1. Tie-2 expression 
seems instead primarily HIF-2α-dependent. Other important factors for tumor 
angiogenesis are PDGF-B and the Matrix Metalloproteinases (MMP)-2 and -9, 
both induced by HIF-1α, and the membrane type-1-MMP, mainly regulated by HIF-
2α. Although cancer angiogenesis is defective, it is in most cases able to support 
the rapid growth of tumor mass. It is evident that a crucial contribution to this 
outcome depends on the decreased oxygen requirement of cancer cells due to the 
resetting of their metabolism also induced by HIF. 
The last step in the natural history of malignant neoplasias is the formation of 
metastasis. HIF are involved also in this mechanism, via the induction of the axis 
CXCL12/SDF1-CXCR4. CXCL-12, also known as Stromal cell-Derived Factor 
(SDF) 1, is a member of a large family of structurally-related chemo-attractive 
cytokines, important for recruitment and homing of several types of cells including 
stem cells. CXCL12/SDF1, through the interaction with its receptor CXCR4, plays 
an important role in the directional migration of metastatic tumor cells. CXCR4 is 
the most common chemokine receptor expressed in tumors and CXCL12/SDF1 is 
highly expressed at the sites of metastasis, including lung, BM, and liver [89]. It 
has been shown that HIF-1α is a potent inducer of the expression of both CXCR4 
and CXCL12/SDF1 in a variety of cell types, such as BM and endothelial cells, as 
well as non-small cell lung cancer and glioblastoma cells. 
Homing of cancer cells is favored by the Epithelial-to-Mesenchymal 
Transition (EMT). EMT is a key feature of invasive cells and it is characterized by 
the loss of epithelial cell-to-cell contacts and the acquisition of mesenchymal 
features and motility. HIF-1α influences the expression of many EMT regulators 
such as E-Cadherin (important for cell-to-cell contact) and LOX (an extracellular 
matrix remodeling enzyme). HIF-1α down-regulates E-Cadherin and enhances 
LOX, thereby favoring cell mobilization. 
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HIF in Cancer Stem Cells 
Hypoxia has been shown to regulate pluripotency as well as proliferation of 
human Embryonic Stem (hES) cells. HIF-2α maintains pluripotency and 
proliferation of hES cells by regulating the expression of POU5F1, SOX2 and 
NANOG, which are transcription factors essential to maintain the pluripotent hES 
cell phenotype. In these cells, interestingly, HIF-3α seems to play a central role in 
hypoxia as well as normoxia by regulating the expression of both HIF-1α and HIF-
2α [90]. Recently, it has been found that either HIF-1α or HIF-1β induce Wnt/β-
catenin in both hES cells and Neural Stem Cells (NSC), drawing key parallels 
between embryonic and adult stem cells. In ES cells, HIF-1α directly binds the 
promoters of Lef1 and Tcf1 and mediates Wnt activation [91]. Several reports 
showed a strong correlation between hypoxia, HIF-α and stem cell genes, 
indicating in particular that HIF-1α induces the expression of the Notch 
transcriptional targets HES1 and HEY2, while HIF-2α promotes that of Oct4 [92]. 
Finally, other studies showed that incubation in hypoxia significantly improves the 
generation of colonies by induced Pluripotent Stem (iPS) cells [93]. 
Evidences for a strong correlation between HIF and a more immature 
phenotype are found also in many types of cancer. For example, HIF-1α expands 
a sub-population of glioma cells positive for CSC marker, such as CD133 and 
CD44 [94], while the expression of HIF-2α is characteristic of neuroblastoma and 
breast cancer cells with a more immature phenotype that correlates to poor 
prognosis [95]. In glioblastoma cells, different (protein and mRNA) expression 
levels of HIF-1α and HIF-2α have been shown between CSC and the cancer cell 
bulk, being HIF-2α expressed in stem cells and HIF-1α in both stem and non-stem 
cells. However, HIF-1α is stabilized only under the more severe hypoxic conditions 
(oxygen <1%) and CSC with low levels of HIF-1α are unable to form tumors and 
exhibit reduced survival in vitro [96]. 
On the basis of all above, we can reach three conclusions: A) HIF-1α is 
especially important during response to acute hypoxia (within 48 hours), whereas 
HIF-2α is more important for long permanence in hypoxia, where it drives the 
selection of an immature/stem phenotype; B) the latter property supports the 
concept of “stem cell niche” as a tissue site where one of the most characteristic 
micro-environmental features is hypoxia; C) the CSC phenotype may be flexibly 
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induced in cancer cells depending on internal and external signals such as 
hypoxia, so that the fraction of a cancer cell population which can be considered to 
represent CSC is phenotypically variable. 
HIF in Chronic Myeloid Leukaemia 
Many studies demonstrated that HIF has important roles in the leukaemia. 
HIF is overexpressed in many types of blood cell cancer, such as ALL and CML, 
often even under normoxic conditions [97].  
Recent studies demonstrated an up-regulation of CXCR4 and CXCL12/SDF1 
in AML as well as niche cells, suggesting that HIF-1α is important to recruit LSC in 
the hypoxic niche and thereby to the maintenance of MRD and progression of the 
disease [98, 99]. HIF-1α-mediated VEGF expression is also involved in blood cell 
cancer, as it stimulates proliferation and the expression of anti-apoptotic proteins 
such BCL2.  
With respect to CML, Mayerhofer et al., demonstrated that BCR/ABL promote 
the expression of HIF-1 through a pathway involving PI3-kinase and mTOR [100]. 
Using a CML mouse model, Zhang and colleagues demonstrated that HIF-1α 
plays an important role in the survival maintenance of CML LSC. HIF-1α deletion 
impaired indeed the propagation of CML by restraining cell-cycle progression and 
inducing apoptosis of LCS. Moreover, they demonstrated that LSC, compared with 
normal HSC, are more addicted to HIF-1 pathway [101]. 
HIF-1 pharmacological inhibitors 
Several pharmacological inhibitors of HIF-1 have been identified. In this 
study, our attention was focused on three different inhibitors (Figure 9) with 




KC7F2 is a nonspecific HIF-1α inhibitor, which down-regulates HIF-1α 
protein synthesis via the PI3K-Akt-mTOR pathway, in particular via the inhibition of 
the protein translation mediated by the complex mTORC1. KC7F2, in fact, inhibits 
the phosphorylation of 4EBP1. This results in the inactivation of the eukaryotic 
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translation initiation factor 4E (eIF-4E) and in the consequent inhibition of protein 
synthesis [102]. KC7F2 treatment in vitro of different neoplastic cell lines, e.g. 
glioma, breast and prostate cancer, inhibits HIF-mediated transcription and 
induces growth arrest. The cytotoxic effect of the treatment is enhanced under 
hypoxic incubation [102]. 
Compound X is another inhibitor of HIF-1 activity. Compound X is already 
FDA approved for a non-oncological use in humans. 
YC-1 [3 -(5' - hydroxymethyl-2' -furyl)-1-benzyl indazole] inhibits HIF-1α activity by 
both promoting its degradation [103, 104] and inhibiting its synthesis via the mTOR 
pathway [104]. More recently, Shan Hua Li and colleagues identified another and 
more specific mechanism by which YC-1 inhibits HIF-1 activity: it disrupts the 
binding between HIF-1α and p300, a co-activator indispensable for the 
transcription initiation of the HIF-1α-downstream genes [105]. However, the 
authors underlined that HIF-1α inhibition resulted different in different cell lines, 
being some cells more sensitive than others. 




 Materials and Methods 
Cells and culture conditions 
K562, KCL22 and primary CML cells were routinely cultured in RPMI 1640 
medium supplemented with 10% fetal bovine serum, 50 units/ml penicillin and 50 
mg/ml streptomycin (all from Euro-Clone, Paington, UK, E.U.) and incubated at 
37°C in a water-saturated atmosphere (21% O2 and 5% CO2). 
K562 [106] and KCL22 [107] are immortalized BCR/Abl positive cell lines 
derived from CML patients in blast crisis. 
K562 cells transfected with shRNA against HIF-1α (shHIF-1α), HIF-2α 
(shHIF-2) or with control shRNA (shRFP), all carrying Red Fluorescent Protein 
were transduced at low multiplicity infection, i.e. about 1 copy of the pro-virus 
(containing two copies of the shRNA) per cell and sorted by FACS on the basis of 
RFP expression. All shHIF-1α, shHIF-2α and shRFP-K562 cells were kindly 
provided by Dr. F. Mazurier, Université Bordeaux 2, Bordeaux. 
Primary CML cells were cultured in the presence of Flt-3 ligand (50 ng/ml), 
TPo (20 ng/ml), SCF (50 ng/ml) and IL-3 (10 ng/ml) in LC1 and of SCF (50 ng/ml), 
G-CSF (100 ng/ml), IL-6 (20 ng/ml), SCF (50 ng/ml) and IL-3 (10 ng/ml) in LC2 (all 
from PeproTech, Rocky Hill, NJ, U.S.A.).  
Experiments were performed with exponentially-growing cells plated at 
3x105/ml and incubated in hypoxia (containing 0.1% O2, 94.9% N2 and 5% CO2) in 
a Whitley DG250 Anaerobic Workstation (Don Whitley Scientific, Shipley, 
Bridgend, UK, E.U.) or normoxia (21% O2 and 5% CO2), at 37°C in a water-
saturated atmosphere. 
Human Embryonic Kidney (HEK) 293T [108] and Mouse embryonic fibroblast 
NIH/3T3 [109] cell lines were routinely cultured in DMEM medium supplemented 
with 10% fetal bovine serum, 50 units/ml penicillin and 50 mg/ml streptomycin (all 
from Euro-Clone, Paington, UK, E.U.) and incubated at 37°C in a water-saturated 




YC-1 (Sigma-Aldrich, No.CAS 170632-47-0) powder was dissolved in 
dimethylsulfoxide (DMSO) and added to cultures at 25 μM at the indicated times. 
KC7F2 (Calbiochem, #400088) powder was dissolved in DMSO and added 
to cultures at 40 μM at the indicated times. 
IM (Santa Cruz, #202180) powder was dissolved in PBS and added to 
cultures at 1 μM at the indicated times. 
Compound X (artificial designation for a biochemical compound that we want 
to keep hidden since the patent is in processing) powder was dissolved in PBS 
and added to cultures at 5 μM at the indicated times (cell lines and primary cells). 
Compound X was added to cultures at 1 μM when was administered in 
combination with IM. In the colony assay, Compound X was added to cultures at 
the indicated concentrations. In the in vivo experiments, the mice were treated 
daily with Compound X (2 mg/kg) via intraperitoneal injection for 2 weeks.  
5-FU (Sigma, Cat # 6627) powder was dissolved in PBS and injected into 
donor mice via tail vein (200 mg/kg).  
For in vivo experiments all the drugs were freshly prepared. 
Isolation of mononuclear cells from human BM aspirates by 
density gradient 
Primary CML cells were collected at the Division of Hematology of Azienda 
Ospedaliera Universitaria Careggi (AOUC). Informed consent for in vitro research 
and approval of the Ethics Committee of AOUC had been previously obtained. 
Human bone marrow aspirates, diluted 1:1 with Phosphate-Buffered Saline (PBS), 
were carefully layered on top of Ficoll (1.5 ml of Ficoll/2 ml BM aspirate diluted in 
PBS; Cedarlane Laboratories, Ontario, Canada) and centrifuged at 2500 rpm for 
20 minutes at room temperature. The mononuclear ring at the plasma/ficoll 
interface was harvested and washed twice with PBS. Cell pellet, suspended in 
RPMI, was seeded in a 100-mm tissue culture dish and incubated for 3 hours at 
37°C to allow adherent cells to attach to the plate. Cells in suspension were then 
collected and placed in RPMI with the addition of cytokines for subsequent 
experiment (see above). 
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Measurement of cell viability. 
Cell viability was measured by the trypan blue (Sigma-Aldrich, #F-7378) (0.2 
gm, 99.8ml Distilled Water, 0.2% Sodium Azide) exclusion test, that consist on 
counting trypan-negative cells in a haemocytometer. 
Protein separation and detection 
Cells were washed twice with ice-cold PBS containing 100 μM orthovanadate 
and solubilized by incubation for 10 minutes at 95°C in Laemmli buffer. Lysates 
were then clarified by centrifugation (20000 g, 10 minutes, room temperature) and 
protein concentration in supernatants was determined by the BCA method. 
Aliquots containing the same amount of proteins (30-50 μg protein/sample) were 
boiled for 10 minutes in the presence of 100 mM 2-mercaptoethanol, subjected to 
SDS-PAGE in 9–15% polyacrylamide gel and then transferred onto polyvinylidene 
fluoride membranes (Millipore) by electroblotting. 
Membranes were incubated for 1 hour at room temperature in Odyssey 
Blocking Buffer (LI-COR® Biosciences, Lincoln, NE, U.S.A.) diluted 1 : 1 with PBS. 
Membranes were then incubated over night at 4°C in Odyssey Blocking Buffer 
diluted 1:1 with PBS containing 0.1% Tween-20 and the primary antibody. Primary 
antibodies used were: rabbit polyclonal anti-phospho (Tyr245) c-Abl (#2862), 
rabbit monoclonal anti-CAIX (D47G3) (#5649), rabbit polyclonal anti-cleaved 
PARP (#9541), rabbit polyclonal anti-cleaved caspase 3 (#9661), rabbit polyclonal 
anti-phospho-histone H2AX (#9718), all from Cell Signaling Technology (Danvers, 
MA, U.S.A.); rabbit polyclonal anti-histone H4 (#07-108) from Millipore (Darmstadt, 
Germany); mouse monoclonal anti-vinculin (V9131), from Sigma-Aldrich (St. 
Louis, MO, U.S.A.); mouse monoclonal anti-HIF-1α (sc-53546), goat polyclonal 
anti-EPAS-1 (sc-8712), mouse monoclonal anti-caspase 3 (sc-7272); goat 
polyclonal anti-GAPDH (sc-20357), rabbit polyclonal anti-c-Abl (sc-131), rabbit 
polyclonal anti-ERK1 (sc-93), from Santa Cruz Biotechnology (S. Cruz, CA, 
U.S.A.), rabbit polyclonal anti-VEGF (bs-0279R) from Bioss Antibodies (Boston, 
MA, U.S.A.) Anti-phospho c-Abl, anti-c-Abl, anti-EPAS-1, anti-VEGF antibodies 
were diluted 1:500 in PBS containing 0.1% Tween-20. Other antibodies were 
diluted 1:1000 in the same buffer mentioned before. 
34 
 
After extensive washing with 0.1% Tween-20 in PBS, membranes were 
incubated for 1 hour at room temperature in Odyssey Blocking Buffer diluted 1:1 
with PBS containing an IRDye800CW- or IRDye680-conjugated secondary 
antibody (LI-COR®). Mouse and rabbit IRDye800CW- conjugated secondary 
antibodies were diluted 1:20000, goat IRDye680-conjugated secondary antibodies 
1:20000, mouse/rabbit/goat IRDye680-conjugated secondary antibody 1:30000.  
Antibody-coated protein bands were visualized by the Odyssey Infrared 
Imaging System Densitometry (LI-COR®), images were recorded as TIFF files. 
Densitometric analysis was performed using the ImageJ program. 
Culture-Repopulation Ability assay 
This assay estimates the culture repopulating power of normal [110, 111] or 
leukaemic [22, 72, 73] haematopoietic cells undergone a selection treatment (e.g. 
hypoxia, drug treatment) in a primary liquid culture (LC1) by means of their 
transfer in fresh medium to non-selective conditions (e.g. normoxia, without 
Figure 10. The Culture-Repopulation Ability (CRA) and the Marrow-Repopulation 




treatment) in a growth-permissive secondary culture (LC2) and the measure of its 
repopulation following a further incubation therein. Cell subsets rescued from LC1 
at different times repopulate LC2 with different kinetics, the time necessary to 
reach the peak of LC2 repopulation reflecting the hierarchical level of 
stem/progenitor cells enriched in LC1. The CRA assay is a non-clonogenic assay 
capable to reveal in vitro stem cells endowed with marrow-repopulating ability in 
vivo [110]. The adaptation of CRA assay to leukaemia cell populations enabled to 
detect different subsets of leukaemia stem or progenitor cells [22, 72-74]. The 
standard version of CRA assay used for leukaemia studies is shown in Figure 10. 
Mice 
C57BL/6J-CD45.1 mice were obtained from The Jackson Laboratory (Bar 
Harbor, ME, U.S.A.). All mice were bred and maintained in a temperature- and 
humidity-controlled environment and given unrestricted access to 6% chow diet 
and acidified water. 
In vitro methylcellulose colony formation assay 
Murine BM cells were obtained by flushing femurs and tibiae. The recovered 
cells were washed once in PBS and incubated 10 minutes at 4°C with red blood 
cell lysis buffer (150 mM NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA, pH 7.4) to 
remove red blood cells. Cells were washed with PBS to eliminate residual buffer. 
The cell pellet was suspended in RPMI and cells were counted by trypan blue 
exclusion assay.  
Human mononuclear cells were harvested by centrifugation in a Ficoll-
Hypaque gradient from BM aspirates (see above). 
3x104  (murine or human) cells were suspended in 100μl of IMDM with 2% 
FBS, 0.1% ciprofloxacina and 100U/ml Penicillin/Streptomicin. Murine or human 
cells were then added to 1ml of Methylcellulose medium H4435 (Stem Cell 
Technology, #04435) or M3234 (Stem Cell Technology, #03234) respectively. 
Compound X or IM were added to the mixture and the cells were plated onto 35-
mm tissue culture dishes and incubated at 37°C in humified air. Each treatment 
condition was performed in duplicate. Colonies were counted under microscope at 
day 10, 17 or 21 of incubation. 
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Transformation of competent cells 
50μl of Subcloning Efficiency DH5α Competent Cells (Life Technologies, # 
18265-017) were thawed on ice. 1-10 ng of DNA (MSCV-IRES-GFP (MIG), 
MSCV-BCR/ABL-IRES-GFP (MIG-BCR/ABL) or MCV-Ecopac [112] plasmids) 
were added to the 1.5 ml microcentrifuge tube containing DH5α cells. Tube was 
incubated for 30 minutes on ice, then 20 seconds in a 42°C water bath and on ice 
for 2 additional minutes. 950 μl of autoclaved Luria Broth (LB) (10 g Tryptone, 5 g 
Yeast Extract, 10 g NaCl, 1 L H20) were added to the tube containing DNA and 
DH5α cells and incubated for 1 hour at 37 °C at 225 rpm. 200 μl of the solution 
were spread on pre-warmed LB Agar plates (10 g Tryptone, 5 g Yeast Extract, 10 
g NaCl, 15g Agar, 1 L H20) containing Ampicillin (75 μg/ml). The plates were 
incubated overnight at 37°C. 
Single colonies were then picked, transferred to flasks containing 500 ml LB, 
and incubated overnight at 37°C. 
Plasmid extraction 
500 ml culture of DH5α cells in LB (see above) were centrifuged (6000g, 4°C, 
10 minutes in Sorvall GSA/GS-3 and Beckman JA-10 rotors) and the pellet 
resuspended in 4 ml glucose/Tris/EDTA solution (20 ml 0.5M EDTA, 25 ml 1M Tris 
Hcl pH 8, 9 g D-Glucose) with the addition of 25 mg/ml hen eff white lysozyme 
(American Bioanalytical, #01148-00005) in glucose/Tris/EDTA solution and 
incubated at room temperature for 10 minutes. The pellet was then incubated on 
ice for 10 minutes with 10 ml of freshly prepared NaOH/SDS solution (10% SDS, 
0.5ml 10N NaOH, 22ml H2O). 7.5 ml of potassium acetate solution (240 ml 5M 
KAc, 46 ml Acetic Acid, 114 ml H2O) were added and the pellet was incubated for 
10 additional minutes on ice. After centrifugation (10 minutes at 4°C, 20000 g) the 
supernatant was decanted into a clean tube and incubated 5-10 minutes at room 
temperature with 6% isopropanol. The solution was centrifuged at room 
temperature for 10 minutes at 15000 g and the pellet was washed with 70% 
Ethanol and dried under vacuum. The pellet was then suspended with 2 ml of TE 
solution (10 mM Tris HCl pH8, 1 mM EDTA pH 8). When the pellet was solubilized 
2.2 g of CsCl and 200 ml Ethidium Bromide (EB) were added and the tube was 
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centrifuged at room temperature for 5 minutes at 4000 rpm. The supernatant was 
transferred into a new ultracentrifuge tube using an 18 ½ G needle and centrifuged 
overnight (90000 rpm, 20°C). The middle dark-pink layer containing the plasmidic 
DNA was collected, transferred into a new ultracentrifuge tube and centrifuged for 
7 hours (90000 rpm, 20°C). The middle dark-pink layer was transferred into a 
clean 15ml tube and EB trough several washing with Isobutanol (until the solution 
turned clear). The clear solution was then transferred into a dialysis membrane 
and incubated for 16-18 hours at 4°C in 1 L of TE 1x. The solution was replaced 
with fresh TE and the membrane was incubated in the same condition for 3 
additional hours. The membrane content was collected into a 15ml tube and 
incubated for 1 hour at 4°C with 100% Ethanol (2 times of the volume transferred 
into the tube) and 3 M NaOAc (10% of the final volume). The tube was then 
centrifuged (3000 g, 4°C, 10 minutes). The pellet was washed with 70% ethanol, 
dried and resuspended in 500 μl-1 ml of sterile H2O. The DNA content was 
measured with a NanoDrop spectrophotometer (Thermo scientific). 
Generation of retroviral stocks 
The retroviral constructs MIG, MIG-BCR/ABL were used to generate high-
titer, helper free, replication-defective ecotropic viral stock by transient transfection 
of 293T cells. The day before transfection, HEK293T cells were plated in 60-mm 
tissue culture dish (4x106 cells/dish) in RPMI. On the day of transfection, the cell 
medium was removed and 4ml of fresh RPMI were added to the dish. 10 μg of 
MIG or MIG-BCR/ABL plasmid and 5 μg of MCV-Ecopac plasmid [112] were 
added to a 15 ml tube with 62 μl CaCl2 and sterile water (to 500 μl total volume). 
2X HBS (500 μl) were added to the tube. The solution was briefly vortexed and 
gently dropped to the 293T cells. Cells were incubated at 37°C for 24 hours. The 
medium was then removed and 4 ml of fresh RPMI were added to the dish. 48 
hours post-transfection of HEK293T the supernatant was collected, filtered 
through 0.45μm syringe and aliquoted in 15 ml tubes (4 ml of virus 
supernatant/tube). The tubes were stored at -80°C. 
To test the viral titer the frozen supernatants were thawed and diluted 1:2 
and 1:8 in RPMI medium. Polybrene (80 μg/mL) was added into the retroviral 
supernatant. The supernatant was then added to NIH/3T3 cells (plated the day 
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before in 100-mm tissue culture dishes, 0.6x105 cells/dish). Cells were incubated 
at 37°C for 3 hours. After the incubation, the virus supernatant was removed and 
10 mL of DMEM were added to the plate containing NIH3T3 cells. The medium 
was collected after additional 48 hours of incubation at 37°C. The percentage of 
GFP expressing cells was evaluated using flow cytometry analysis. Good retroviral 
supernatant means the GFP% can reach 90-95% at the 1:2 dilution and 75-85% at 
1:8 dilution. 
BM cells transduction and transplantation 
5-FU powder was freshly suspended in PBS and incubated 10-30 minutes at 
37°C in a water bath. Donor mice were injected with 5-FU via tail vein (200mg/kg) 
and after 4 days they were sacrificed with CO2 and femurs and tibiae were 
collected. BM cells were flushed out with RPMI, usually 2-3x107 total BM cells 
were harvested from 10 mice. Cells were centrifuged (1500 rpm, 10 minutes) and 
the pellet was resuspended in 10 ml of the first stimulation medium: 77% DMEM, 
15% FBS, WEHI-3B conditioned medium, penicillin-streptomycin, 1mg/ml 
ciprofloxacin, 200nM L-glutammine, 6 ng/ml recombinant murine IL-3 (Peprotech, 
# 213-13), 10 ng/ml recombinant murine IL-6 (Peprotech, # 250-16) and 50-100 
ng/ml recombinant murine SCF (Peprotech, # 250-03). Cells were incubated at 37 
°C for 24 hours. Cells were then collected, centrifuged (10 minutes, 1500 rpm, 
room temperature) and resuspended in 4 ml of transduction medium: 50% 
retroviral supernatant, 27% DMEM, 15% FBS, 5% WEHI-3B conditioned medium, 
penicillin-streptomycin, 1 mg/ml ciprofloxacin, 200 nM L-glutammine, 6 ng/ml 
recombinant murine IL-3 (Peprotech, # 213-13), 10 ng/ml recombinant murine IL-6 
(Peprotech, # 216-16), 50-100 ng/ml recombinant murine SCF (Peprotech, # 250-
03), 1% HEPES and 20 μg/mL polybrene. BM cells were transferred into a 6-well 
plate and centrifuged at 2300 rpm at room temperature for 90 minutes. Cells were 
then resuspended and incubated at 37°C for 3 hours. At the end of the incubation, 
the supernatant was removed and BM cells were incubated overnight at 37 °C with 
4ml of stimulation medium (see above) per well. At the end of the incubation, 2 ml 
of stimulation medium were removed and 2 ml of transduction medium (2 ml of 
retroviral supernatant, 20 μg/ml polybrene, 1% HEPES) were added to each well. 
Cells were centrifuged (2300 rpm, for 90 minutes) and incubated at 37°C for 3 
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hours. At the end of the incubation BM cells were collected, centrifuged (1500 rpm, 
10 minutes) and resuspended in PBS. The amount of PBS was adjusted to inject 
300 μl/recipient mouse (0.5x106 BM cells). 
Recipient mice had been previously treated by two doses of 550-cGy 
gamma, separated by two hours. 
Flow cytometry analysis of murine BM LSK cells. 
Mice BM cells harvested from femurs and tibiae were incubated 10 minutes 
at 4°C with red blood cell lysis buffer (see above) to eliminate red blood cells. Cells 
were washed once, resuspended in PBS and incubated for 30 minutes at 4°C with 
a biotin-labeled lineage antibody cocktail (Miltenyl Biotec, #120-003-582) 
containing a mixture of antibodies labeling lineage-committed cells. Cells were 
then washed with PBS and incubated for 15 minutes at 4°C with the fluorochrome-
labeled secondary antibody (allophycocyanin-Cy7-conjugated streptavidin) for 
recognizing biotin, PE-conjugated anti-c-kit (eBioscience, # 12-1171-82) and 
allophycocyanin-conjugated anti-Sca-1 (eBioscience, # 17-5981-82). Cells were 
then washed and resuspended in PBS. 7AAD was added to the cells before flow 
cytometric analysis. Flow cytometry analysis was performed on lineage-
negative/Sca-1-positive/c-kit-positive (LSK) cells. Results were analyzed using the 
FlowJo program. 
Statistical Analysis 
All experiments were performed in triplicate or higher numbers of repeats. 
Statistical significance was evaluated by Student’s t-test for paired samples; p 




Results and Discussion 
Genetic inhibition of HIF1-α or HIF2- α impairs the Culture-
Repopulation Ability of hypoxia-selected BCR/Abl-negative 
Leukaemia Stem Cells. 
The aim of this study was to address the effects of the pharmacological 
inhibition of HIF-1α on the maintenance of CML stem cells potential. It has already 
been demonstrated, in fact, that the genetic suppression of HIF-1α antagonized 
the propagation of CML by impairing cell-cycle progression and inducing apoptosis 
of LSC [101]. 
First we wanted to evaluate the effect of CML cell lines hypoxic incubation on both 
the expression and the activity levels of HIF-1α. As shown in Figure 11, in K562 
and KCL22 cells HIF-1α is expressed also in normoxia (time 0 of incubation). HIF-
1α expression in normoxia has already been observed in other blood cancers [97]. 
Nevertheless, HIF-α transcriptional activity increased in hypoxia, as indicated by 
Figure 11. Hypoxia enhances CA-IX expression in CML cell lines. K562 (A) and 
KCL22 (B) cells were incubated in deep hypoxia (~0.1% O2) for the indicated times. Total 
cell lysates in Laemmli buffer were subjected to immuno-blotting with the indicated 
antibodies. Anti-GAPDH antibody was used to verify equalization of protein loading. One 
representative experiment out of 3 is shown. 
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the expression of CA-IX, one of the HIF-1α target genes, in both K562 and KCL22 
cells. Different mechanisms may explain this result. In aerobic conditions, nuclear 
shuttling of HIF-1α could be diminished resulting in a predominant cytoplasmic 
localization of HIF-1α and binding to the HRE sequence on the DNA partially 
(K562) or totally (KCL22) impaired. Hypoxia would then relief this block thus 
allowing gene target expression. Another possibility is that the promoter of the CA-
IX gene could be more accessible in hypoxic conditions. This second hypothesis is 
supported by the fact that hypoxia does not change the expression of VEGF, 
another HIF-1α target gene (Figure 15 B).  
The effects of HIF-1α or HIF-2α suppression on the selection of LPC/LSC subsets 
in hypoxic cultures were then tested. We used K562 cells stably transfected with 
shRNA against HIF-1α (shHIF-1α) or HIF-2 α (shHIF-2 α) or control scrambled 
shRNA (shRFP), all containing the Red Fluorescent Protein (RFP). The genetic 
Figure 12. Genetic suppression of HIF-1α or HIF-2α and its effects on the kinetics of 
K562 cell number in hypoxia. K562 cells stably transfected with shRNA against HIF-1α 
(shHIF-1α), HIF2-α (HIF-2α) or control scrambled shRNA (shRFP) were incubated in 
deep hypoxia (~0.1% O2) for the indicated times. (A) Total cell lysates in Laemmli buffer 
were subjected to immuno-blotting with the indicated antibodies. Anti-vinculin antibody 
was used to verify equalization of protein loading. One representative experiment out of 3 
is shown. (B) Trypan blue-negative cells were counted at the indicated times. Values 
represent mean ± S.E.M. of data obtained from 3 independent experiment.  
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inhibition of HIF-1α or HIF-2α protein was successful, as revealed by immuno-
blotting (Figure 12A). Incubation of these cells in hypoxia showed that their 
number in culture decreased with a kinetics unaffected by HIF-1α or HIF-2α 
suppression. This result indicates that HIF-1α and HIF-2α are not necessary for 
the maintenance of K562 cell bulk in the course of incubation in hypoxia (Figure 
12B).  
The effects of the genetic inhibition of HIF1- α or HIF-2α on the 
maintenance of LPC and LSC in hypoxia were then determined by CRA assay. 
Cell transfected with shHIF-1α, shHIF-2α or shRFP were incubated in hypoxic 
primary cultures (LC1) for different times (3 or 7 days) and then replated into 
Figure 13. Effects of HIF-1α or HIF-2α genetic suppression on the maintenance of 
LPC or LSC potential in hypoxia. K562 cells stably transfected with shRNA against 
HIF-1α (shHIF-1α), HIF2-α (HIF-2α) or control scrambled shRNA (shRFP) were incubated 
in hypoxic (~0.1% O2) LC1 and transferred at day 3 (A) or 7 (B) into normoxic LC2, to 
determine the maintenance of LPC or LSC (respectively) in LC1. Trypan blue-negative 
cells were counted at the indicated times of LC2. Values represent mean ± S.E.M. of data 
obtained from 3 independent experiments. 
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normoxic secondary cultures (LC2). The kinetics of the LC2 repopulation is shown 
in Figure 13. Cells transferred from day-3 hypoxic LC1 repopulated LC2 after a 4- 
day long lag-phase, to reach the peak at day 11 (Figure 13A). Such a CRA pattern 
corresponds to LPC resistant to hypoxia but not hypoxia-selected [73]. The 
suppression of HIF-2α did not significantly affect the CRA of LPC. On the contrary, 
hypoxia strongly inhibited the CRA of cells were shHIF1-α was suppressed (Figure 
13A). Thus, clonal expansion of LPC requires the expression of HIF-1α but not 
HIF-2α. The CRA of cells transferred to LC2 from day-7 hypoxic LC1, is shown in 
Figure 13B. At day 7 of incubation in hypoxia, the selection of BCR/Abl-negative 
LSC of CML is complete [73]. Control cells repopulated LC2 after a 17-day lag-
phase, reaching the peak at day 24. This repopulation was suppressed by cell 
transfection with either shHIF-1α or shHIF-2α. Thus, the maintenance of LSC in 
hypoxia requires the activity of both HIF-1α and HIF-2α. 
Pharmacological inhibition of Hypoxia-Inducible Factor-1α 
induced apoptosis in K562 and KCL22 cell bulk. 
The effects of three HIF-α pharmacological inhibitors, with different 
mechanism of action, were then tested. KC7F2 and YC-1 inhibit HIF-1α activity 
only [102-104], while Compound X inhibits both HIF-1α and HIF-2α activity. K562 
and KCL22 cells were incubated in hypoxia for 1, 2, 3 or 7 days in the absence or 
the presence of one of the three drugs. Inhibitors were added at time zero, i.e. 
immediately before the beginning of incubation in hypoxia. 
When added to hypoxia-incubated K562 cell cultures, YC-1 and KC7F2 did 
not inhibit HIF-1α activity, as determined by testing their effects on the expression 
of CA-IX (Figure 14A and 14B). It is worth pointing out that the proposed 
mechanism of action of the two drugs should operate at the translational level, 
implying a decrease of HIF-1α protein expression, which was not observed in our 
conditions. Similar results were obtained for KCL22 cells (data not shown). Since 
YC-1 and KC7F2 were solubilized in DMSO we tested possible effects of this 
compound, in the absence of the inhibitors, on HIF-1α or CA-IX expression level. 
DMSO did not affect either HIF-1α or CA-IX (Figure 14C). 
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Compound X was also tested, under conditions identical to those of Figure 14. 
Compound X, differently from YC-1 and KC7F2, inhibited HIF-1α transcriptional 
activity. Treatment indeed, inhibited the expression of CA-IX (K562 or KCL22 cells; 
Figure 15A and 15C) as well as of VEGF (K562 cells), another HIF-1α target 
protein (Figure 15B). As expected, the level of HIF-1α protein expression was not 
Figure 14. Effects of YC-1, KC7F2 or DMSO on HIF-1α and CA-IX expression in 
K562 cells. Exponentially-growing K562 cells from routine cultures were replated in fresh 
medium at 3x105 cells/ml and incubated in hypoxia (~0.1% O2) for the indicated times. 
Cultures were treated or not with 25 µM YC-1 (A) or 40 µM KC7F2 (B) or 0.1%DMSO (C) 
at time 0 of incubation, i.e. at the beginning of incubation in hypoxia. Total cell lysates in 
Laemmli buffer were subjected to immuno-blotting with the indicated antibodies. Anti-
GAPDH was used to verify equalization of protein loading. One representative 
experiment out of 3 is shown.  
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affected by Compound X, which inhibits the binding between the HIF subunits α 
and β (Figure 15A and 15C).To determine the effects of the three drugs on 
survival and growth of CML cell lines, exponentially-growing KCL22 or K562 
cultures were incubated in hypoxia for 1, 2, 3 or 7 days without treatment or in the 
presence of one of the three inhibitors or DMSO. Inhibitors were added at time 0, 
or after 1 day of hypoxic incubation. Growth kinetics were determined by counting 
viable cells via trypan-blue exclusion at days 1, 2, 3 and 7 of incubation. The 
number of viable cells, in control K562 or KCL22 cultures, increased about 2-fold 
over the first 3 days of incubation, to decrease thereafter (Figure 16A and 16B, 
17A and 17B, 18A and 18B). YC-1 treatment of K562 cells did not affect growth  
 
Figure 15. Effects of Compound X on the expression of HIF-1α, CA-IX and VEGF in 
K562 or KCL22 cells. Exponentially-growing K562 (A and B) or KCL22 (C) cells from 
routine cultures were replated in fresh medium at 3x105 cells/ml and incubated in hypoxia 
(~0.1% O2) for the indicated times. Cultures were treated or not with 5 µM Compound X 
at time 0 of incubation, i.e. at the beginning of incubation in hypoxia. Total cell lysates in 
Laemmli buffer were subjected to immuno-blotting with the indicated antibodies. Anti-
GAPDH antibody was used to verify equalization of protein loading. One representative 




Figure 16. Effects of YC-1 on cell growth, apoptosis and DNA damage in 
hypoxia. Exponentially-growing K562 (A and C) or KCL22 (B and D) cells from routine 
cultures were replated in fresh medium at 3x105 cells/ml and incubated in hypoxia (~0.1% 
O2) for the indicated times. Cultures were treated or not with 25µM YC-1 or 0.1% DMSO 
(the vehicle of drug administration) at time 0, i.e. at the beginning of incubation in hypoxia 
(t0) or after a 1 day long pre-incubation in hypoxia (d1). (A and B) Trypan blue-negative 
cells were counted at the indicated times. Values represent mean ± S.E.M. of data 
obtained from 3 independent experiments. (C and D) Total cell lysates in Laemmli buffer 
were subjected to immuno-blotting with the indicated antibodies. Anti-GAPDH or anti-H4 
antibodies were used to verify equalization of protein loading. One representative 




Figure 17. Effects of KC7F2 on cell growth, apoptosis and DNA damage in hypoxia. 
Exponentially-growing K562 (A and C) or KCL22 (B and D) cells from routine cultures 
were replated in fresh medium at 3x105 cells/ml and incubated in hypoxia (~0.1% O2) for 
the indicated times. Cultures were treated or not with 40 µM KC7F2 or 0.1% DMSO (the 
vehicle of drug administration) at time 0, i.e. at the beginning of incubation in hypoxia (t0) 
or after a 1 day long pre-incubation in hypoxia (d1). (A and B) Trypan blue-negative cells 
were counted at the indicated times. Values represent mean ± S.E.M. of data obtained 
from 3 independent experiments. (C and D) Total cell lysates in Laemmli buffer were 
subjected to immuno-blotting with the indicated antibodies. Anti-GAPDH or anti-H4 
antibodies were used to verify equalization of protein loading. One representative 




kinetics (Figure 16A), whereas that of KCL22 cells suppressed the increase of 
viable cell number occurring between time 0 and day 2 (Figure 16B). The immuno-
blotting confirmed the absence of apoptosis or DNA damage in YC-1-treated cells: 
the treatment, indeed, did not alter the levels of the cleaved form of caspase 3 or 
of histone H2AX phosphorylation (Figure 16C). 
The treatment of K562 cells with KC7F2 at time 0, but not day 1, suppressed 
the increase of the number of viable cells occurring in control cultures from time 0 
to day 2 (Figure 17A). The treatment of KCL22 cells; either at time 0 or day 1, 
significantly reduced the number of viable cells in culture, indicating that KCl22 
cells were more sensitive than K562 cells to the drug (Figure 17B). This fact does 
not exclude that higher doses would elicit similar effects in K562 cells. The 
immuno-blotting confirmed that KC7F2 administration at time 0 induced apoptosis 
in both cell lines (Figure 17C and 17D). In KCL22 cell cultures, treatment at day 1 
also induced apoptosis (Figure 17D), in keeping with the results of figure 17 B. 
Interestingly, the treatment of K562 cells with KC7F2 at time 0 induced DNA 
damage, as indicated by the phosphorylation of H2AX histone (Figure 17C).The 
treatment of K562 cells with Compound X  at time 0 suppressed the increase of 
the number of viable cells occurring in control cultures from time 0 to day 2 (Figure 
18A). The treatment of KCL22 cells, either at time 0 or day 1, significantly reduced 
the number of viable cells in culture (Figure 18B), indicating that KCL22 cells were 
more sensitive than K562 cells to Compound X, like they were to KC7F2. This 
results are in contrast with those obtained via shRNA-mediated HIF-1α 
knockdown, which did not decrease the number of viable cells in hypoxia (Figure 
12B). This discrepancy can be explained by the fact that, in those experiments, the 
lack of HIF1-α could be compensated for by the expression of HIF2-α. On the 
contrary, Compound X, inhibiting simultaneously both HIF1-α and HIF2-α, 
impaired this compensation. The activation of the apoptotic pathway, by 
Compound X, is shown in the immuno-blotting of Figure 18C and 18D: the 
caspase 3 cleavage occurred in both cell lines following treatment at time 0 and in 
KCL22 cells also at day 1. The activation of caspase pathway was confirmed by 
the increase of the cleaved Poly ADP-Ribose Polymerase (PARP) (Figure 18C). 
DNA damage as indicated by the phosphorylation of the histone H2AX, occurred in 





Figure 18. Effects of Compound X on cell growth, apoptosis and DNA damage in 
hypoxia. Exponentially-growing K562 (A and C) or KCL22 (B and D) cells from routine 
cultures were replated in fresh medium at 3x105 cells/ml and incubated in hypoxia (~0.1% 
O2) for the indicated times. Cultures were treated or not with 5µM Compound X at time 0, 
i.e. at the beginning of incubation in hypoxia (t0) or after a 1 day long pre-incubation in 
hypoxia (d1). (A and B) Trypan blue-negative cells were counted at the indicated times. 
Values represent mean ± S.E.M. of data obtained from 3 independent experiments. (C 
and D) Total cell lysates in Laemmli buffer were subjected to immuno-blotting with the 
indicated antibodies. Anti-GAPDH or anti-H4 antibodies were used to verify equalization 




The lack of effect of cell treatment with DMSO, the vehicle of YC-1 and 
KC7F2 administration, alone on the number of viable cells in culture is shown in 
Figure 19A and B, while that on the activation of apoptosis is shown in Figure 19C. 
The latter results are in keeping whit those of Figures 16D and 17D. 
Figure 19. Effects of DMSO alone on cell growth, apoptosis and DNA damage in 
hypoxia. Exponentially-growing K562 (A and C) or KCL22 (B) cells from routine cultures 
were replated in fresh medium at 3x105 cells/ml and incubated in hypoxia (~0.1% O2) for 
the indicated times. Cultures were treated or not with 0.1 % DMSO at time 0, i.e. at the 
beginning of incubation in hypoxia (t0) or after a 1 day long pre-incubation in hypoxia 
(d1). (A and B) Trypan blue-negative cells were counted at the indicated times. Values 
represent mean ± S.E.M. of data obtained from 3 independent experiments. (C) Total cell 
lysates in Laemmli buffer were subjected to immuno-blotting with the indicated 
antibodies. Anti-GAPDH antibody was used to verify equalization of protein loading. One 




Compound X impaired the Culture-Repopulation Ability of 
hypoxia-selected BCR/Abl-positive and BCR/Abl-negative 
Leukaemia Progenitor Cells. 
The effects of the three inhibitors on the maintenance of BCR/Abl-positive 
and BCR/Abl-negative LPC resistant to hypoxia were tested by CRA assay. Cells 
were incubated, at a density of 3x105 cells/ml, in hypoxic LC1 for 2 or 3 days in the 
absence or in the presence of DMSO or of one of the drugs. The treatment was 
administered at time 0 or after 1 day of pre-adaptation to hypoxia. Cells were then 
washed free of drug and transferred at a density of 3x104 cells/ml to drug-free, 
growth-permissive (normoxic) LC2.  
Figure 20. Effects of YC-1, KC7F2 or Compound X on the CRA of BCR/Abl–positive 
LPC. Exponentially-growing K562 (A, C and E) or KCL22 (B, D and F) cells from routine 
cultures were replated in fresh medium at 3x105 cells/ml and incubated in hypoxic LC1 
(~0.1% O2) for 2 days. Cultures were treated with one of the drugs at time 0, i.e. at the 
beginning of incubation in hypoxia (t0) or after a 1 day long pre-incubation in hypoxia 
(d1). Cells were then transferred into normoxic LC2 (3x104 cells/ml) and trypan blue-
negative cells were counted at the indicated times of incubation in LC2. Values represent 




Figure 20 shows that control cells transferred from day-2 LC1 rapidly 
repopulated LC2, to peak at day 14 or day 11 (KCL22 or K562 cells, respectively). 
This kinetics is typical of cells transferred to LC2 when BCR/Abl is still fully 
expressed in LC1 (Figure 21). The kinetics of LC2 repopulation was unaffected by 
the treatment with either YC-1 or KC7F2 (Figure 20 A-D). On the contrary, 
treatment with Compound X of hypoxic LC1 suppressed LC2 repopulation as for 
either cell line.  
The effects of cell transfer to LC2 from day-3 hypoxic LC1, where the 
suppression of BCR/Abl has been induced (Figure 21) are shown in Figure 22. 
This cell subset, mainly constituted by BCR/Abl-negative LPC, repopulated LC2 
with a rather different kinetics. After an initial lag-phase of 3-4 days, cell number 
increased slowly to peak at day 14. This kinetics is the consequence of BCR/Abl 
suppression, the delay in LC2 repopulation being due to the time necessary for re-
expression of BCR/Abl following transfer to normoxia. Treatment with YC-1 or 
KC7F2 at time 0 or day 1 of incubation in hypoxic LC1 did not significantly affect 
the kinetics of LC2 repopulation as for K562 (Figure 22A and 22C), or delayed this 
kinetics without reducing CRA substantially in the case of KCL22 cells (Figure 22B 
and 22D). On the contrary, treatment with Compound X of hypoxic LC1 
suppressed LC2 repopulation as for either cell line. Thus Compound X suppressed 
CRA of hypoxia-resistant LPC of CML, irrespective whether they express BCR/Abl 
(Figure 20E and 20F) or not (Figure 22E and 22F). 
Figure 21. Effects of hypoxia on BCR/Abl expression and phosphorylation. 
Exponentially-growing K562 cells from routine cultures were replated in fresh medium at 
3x105 cells/ml and incubated in hypoxia (~0.1% O2) for the indicated times. Total cell 
lysates in Laemmli buffer were subjected to immuno-blotting with the indicated 
antibodies. Anti-GAPDH antibody was used to verify equalization of protein loading. One 




LC2 repopulation by either BCR/Abl-positive or -negative LPC was not affected by 
the addition to cultures of DMSO alone (Figure 23). 
Figure 22. Effects of YC-1, KC7F2 or Compound X on the CRA of BCR/Abl–negative 
LPC. Exponentially-growing K562 (A, C and E) or KCL22 (B, D and F) cells from routine 
cultures were replated in fresh medium at 3x105 cells/ml and incubated in hypoxic LC1 
(~0.1% O2) for 3 days. Cultures were treated with one of the drugs at time 0, i.e. at the 
beginning of incubation in hypoxia (t0) or after a 1 day long pre-incubation in hypoxia 
(d1). Cells were then transferred into normoxic LC2 (3x104 cells/ml) and trypan blue-
negative cells were counted at the indicated times of incubation of LC2. Values represent 




Figure 23. Effects of DMSO on the CRA of BCR/Abl-positive or -negative LPC. 
Exponentially-growing K562 (A and C) or KCL22 (B and D) cells from routine cultures 
were replated in fresh medium at 3x105 cells/ml and incubated in hypoxic LC1 (~0.1% O2). 
0.1 % DMSO was administered at time 0, i.e. at the beginning of the incubation in hypoxia 
(t0) or after a 1 day long pre-incubation in hypoxia (d1). After 2 (A and B) or 3 (C and D) 
days of incubation in LC1, cells were transferred into normoxic LC2 (3x104 cells/ml) and 
trypan blue-negative cells were counted at the indicated times of incubation in LC2. 
Values represent mean ± S.E.M. of data obtained from 4 independent experiments.  
Compound X suppressed the Culture-Repopulation Ability of 
hypoxia-resistant BCR/Abl-negative Leukaemia Stem Cells. 
The effects of the three inhibitors on the maintenance of LSC were tested by 
CRA assay. K562 or KCL22 cells were incubated, at a density of 3x105 cells /ml in 
hypoxic LC1 in the absence or in the presence of DMSO or of one of the drugs. 
The treatment was administered at time 0 or after 1 day of pre-adaptation to 
hypoxia. Cells were rescued from day-7 LC1, i.e. following a one-log reduction of 
total cell number in LC1 and most likely an enrichment of BCR/Abl-negative cells 
[22, 72, 73]. Cells were then washed free of drug and transferred at a density of 
3x104 cells/ml to drug-free, growth-permissive (normoxic) LC2. Untreated, control 
K562 (Figure 24A, 24C and 24E) or KCL22 (Figure 24B, 24D and 24F) cells 
repopulated LC2 with an initial lag-phase of 7 or 4 days, to peak after 24 or 21 
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days. Such a kinetics typically reflects the content of transplanted LC1 cells with 
LSC [72, 73], as well as HSC [110, 111]. 
The treatment of hypoxic LC1 with YC-1 time 0 or day 1 determined a 
reduction and/or a delay of LC2 repopulation by K562 cells rescued from LC1 at 
day 7 (Figure 24A). A similar result was obtained with YC-1 treatment of KCL22 
cells at time 0 of LC1 (Figure 24B). Unexpectedly, KCL22 cells treated with YC-1 
after 1 day of hypoxic pre-incubation, did not repopulate LC2 (Figure 24B). KC7F2 
treatment at time 0 or day 1 of incubation in hypoxia did not alter LC2 repopulation 
by K562 of KCL22 rescued after 7 days of hypoxic LC1 (Figure 24C and 24D). 
Figure 24. Effects of YC-1, KC7F2 or Compound X on the CRA of hypoxia-resistant 
BCR/Abl-negative LSC. Exponentially-growing K562 (A, C and E) or KCL22 (B, D, F) 
cells from routine cultures were replated in fresh medium at 3x105 cells/ml and incubated 
in hypoxic LC1 (~0.1% O2) for 7 days. Cultures were treated with one of the drugs at time 
0, i.e. at the beginning of incubation in hypoxia (t0) or after a 1 day-long pre-incubation in 
hypoxia (d1). Cells were then transferred into normoxic LC2 (3x104 cells/ml) and trypan 
blue-negative cells were counted at the indicated times of incubation in LC2. Values 
represent mean ± S.E.M. of data obtained from 4 independent experiments. 
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Although potentially interesting, this results does not seem due to HIF-1α 
inhibition, as YC-1 and KC7F2 did not inhibit HIF-1α in our conditions and did not 
alter CA-IX expression (Figure 14A and 14B). It should be noted that the latter 
results were obtained in different experimental condition, i.e. administering the 
drugs at time 0. On the other hand, the fact that KC7F2 was not effective on K562 
cells further support the evidence that KCL22 cells are more sensitive than K562 
cells to this drugs.  
Compound X administration to LC1, at either time 0 or day 1 of incubation in 
hypoxia, suppressed LC2 repopulation by cells rescued from LC1 at day 7 (Figure 
24E and 24F). The effects of Compound X are in keeping with those of genetic 
suppression of HIF-1α (Figure 13B).  
No difference was observed between control cultures and cultures where 
DMSO was administered (Figure 25). 
To better mimic the scenario most likely occurring in vivo, we treated K562 or 
KCL22 cell cultures at day 6 of incubation in hypoxia. It is indeed straightforward to 
think that, in vivo, LSC are already established within the SC niches, i.e. adapted 
to a hypoxic environment, before the beginning of treatment. Accordingly, it has 
been demonstrated that hypoxia can protect CSC from several treatments [74, 
Figure 25. Effects of DMSO on the CRA of hypoxia-resistant BCR/Abl-negative LSC. 
Exponentially-growing K562 (A) or KCL22 (B) cells from routine cultures were replated in 
fresh medium at 3x105 cells/ml and incubated in hypoxic LC1 (~0.1% O2). 0.1% DMSO 
was administered at time 0, i.e. at the beginning of the incubation in hypoxia (t0) or after a 
1 day long pre-incubation in hypoxia (d1). After 7 days of incubation in LC1, cells were 
transferred into normoxic LC2 (3x104 cells/ml) and trypan blue-negative cells were 
counted at the indicated times of incubation in LC2. Values represent mean ± S.E.M. of 




113-115]. Cells treated in hypoxic LC1 at day 6 were transferred to normoxic LC2 
at day 9 (Figure 26). Control K562 (Figure 26A) or KCL22 (Figure 26B) cells 
repopulated LC2 with an initial 7-11 day-long lag-phase, respectively, to reach the 
peak around day 21. YC-1 did not affect LC2 repopulation by K562 cells, but 
suppressed that by KCL22 cells. KC7F2 suppressed LC2 repopulation (CRA) by 
either K562 or KCL22 cells. However, as mentioned above, this was not a 
consequence of HIF-1α inhibition.  
Compound X also suppressed the CRA of K562 and KCL22 cells. Thus, 
prolonged adaptation to hypoxia did not confer resistance to Compound X 
treatment, indicating that HIF-1α pharmacological inhibition could be a possible 
therapeutic strategy to target hypoxia-adapted LTR-LSC. DMSO did not alter the 
CRA of K562 or KCL22 rescued after 9 days of hypoxic LC1. 
 
  
Figure 26. Effects of YC-1, KC7F2 or Compound X on the CRA of long hypoxia-
adapted LSC. Exponentially-growing K562 (A) or KCL22 (B) cells from routine cultures 
were replated in fresh medium at 3x105 cells/ml and incubated in hypoxic LC1 (~0.1% 
O2). Cultures were treated with DMSO or one of the drugs at day 6 of incubation and 
transferred into normoxic LC2 at day 9 (3x104 cells/ml). Trypan blue-negative cells were 
counted at the indicated times of incubation in LC2. Values represent mean ± S.E.M. of 




Compound X impaired the Culture-Repopulation Ability of 
hypoxia-selected primary Chronic Myeloid Leukaemia Stem Cells. 
First, we tested the effect of Compound X on the cell bulk of primary cells 
from CML patients. (Figure 27). Human light-density BM mononuclear cells, 
obtained from three CML patients in chronic phase (Figure 27A, 27B and 27C) and 
one CML patient in blast crisis (Figure 27D), were incubated in hypoxia for 7 days 
and treated with Compound X at time 0. In agreement with what observed for cell 
lines, Compound X reduced the number of viable cells in culture. 
The effectiveness of Compound X demonstrated on hypoxia-selected LSC of 
stabilized CML lines was also tested on primary CML cells. Human light-density 
BM mononuclear cells explanted from five chronic-phase and one blast-crisis CML 
patients were treated with Compound X at time 0 and incubated in hypoxia for 7 
days. Cells were then washed free of drug and transferred at a density of 3x104 
cells/ml to drug-free, normoxic LC2 (Figure 28).  
Figure 27. Effects of Compound X on total cell number in primary CML cell cultures 
incubated in hypoxia. Cultures of human light-density BM mononuclear cells obtained 
from CML patients were established with 3x105 cells/ml, treated with Compound X at time 
0 and incubated in hypoxia (~0.1% O2). Trypan blue-negative cells were counted at the 
indicated times of incubation.  
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Cells derived from two CML patients (# 2 and # 4) repopulated LC2 rapidly 
(Figure 28A and 28B) with a kinetics similar to that obtained with BCR/Abl-positive 
LPC of stabilized CML cell lines rescued from LC1 (Figure 20A-F). On the other 
hand, cells derived from patients # 6 and # 7 repopulated LC2 after an initial lag-
phase of 7-10 days (Figure 28E and 28F), with a kinetics similar to that obtained 
replating hypoxia selected LSC of stabilized CML cell lines (Figure 24A-F). Finally, 
cells derived from patients # 1 and # 5 repopulated LC2 with a kinetics that was 
intermediate between the other two groups of patients (Figure 28C and 28D) and 
comparable to that of hypoxia-selected BCR/Abl-negative LPC (Figure 22A-F). In 
keeping with what observed for CML cell lines, Compound X impaired LC2 
repopulation driven by different hypoxia-selected human primary CML cell subsets 
(Figure 28A-F).  
The effects of IM, the standard CML treatment, on the CRA of primary CML 
cells from patient # 7 were tested. Cells were treated with IM at time 0 and 
incubated in hypoxia for 7 days. Contrarily to Compound X, IM did not suppress 
LC2 repopulation. Thus, hypoxia-selected human primary CML cells were 
insensitive to TKi treatment (Figure 28F). This is in agreement with the notion of 
refractoriness of LSC to IM [73]; in this respect, it is worth pointing out that patient 
# 7 was a newly-diagnosed patient, i.e. never treated before, and no BCR/Abl 
mutations have occurred yet. 
Figure 28. Effects of Compound X on the CRA of hypoxia-selected primary LSC of 
CML. Human light-density BM mononuclear cells, obtained from CML patients, were 
treated with Compound X (A-F) or IM (F) and incubated in hypoxic LC1 (~0.1% O2) 
(established at 3x105 cells/ml) for 7 days. Cells were then transferred into normoxic LC2 
(established at 3x104 cells/ml) and trypan blue-negative cells were counted at the 




The combined treatment with Compound X and IM impaired the 
CRA of hypoxia-selected LSC. 
The effects of the combined treatment of Compound X and IM on CML cells 
were then tested. The estimate of half-maximal Inhibitory Concentration (IC50) of 
the two drugs on the number of viable cells in K562 as well as KCL22 cultures 
incubated in hypoxia is reported in Figure 29 (29A, 29B and 29D).  Compound X, 
at a concentration (1 µM) markedly lower than IC50, still reduced CA-IX expression 
(Figures 29C). 
 
Figure 29. IC50 of Compound X and IM on the number of viable cells in CML cell 
cultures in hypoxia. Exponentially-growing K562 or KCL22 cells from routine cultures 
were replated in fresh medium at 3x105 cells/ml and incubated in hypoxia. Cultures were 
treated with the indicated concentration of Compound X or IM. Trypan blue-negative cells 
were counted on day 3 of incubation. Values represent mean ± S.E.M. of data obtained 
from 3 experiments (A, B and D). Total lysates in Laemmli buffer of cells incubated in 
hypoxia for 7 days were subjected to immuno-blotting with the indicated antibodies. 
Values represent ratios between Compound X-treated and -untreated samples with 
respect to CA-IX band densitometry, following normalization as for the relative ERK1/2 
band (used to verify equalization of protein loading) (C). 
The effects of the combined treatment of Compound X and IM on total 
number of viable K562 cells in LC1 incubated in hypoxia and on the maintenance 
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of LSC therein are reported in Figure 30. To prevent the possible toxicity of the 
combination of the two drugs at full doses, as well as to better appreciate the 
effects of their combination, we used both Compound X and IM at 1μM. Cells were 
incubated in hypoxia in the absence or the presence of Compound X or IM, alone 
or in combination, added at time 0. Compound X or IM alone did not significantly 
decrease the number of viable cells in LC1 after 2 days of incubation in hypoxia, 
while the combined treatment determined a significant reduction (Figure 30A). 
Thus, Compound X and IM had an at least additive effect in reducing the number 
of viable cells in culture. 
To establish the effects of drug combination on the CRA of hypoxia-selected 
cells K562 cells were incubated in hypoxic LC1 in the absence or in the presence 
of the drugs alone or in combination for 7 days and then transferred into normoxic 
LC2 (Figure 30B). Control cells repopulated the culture with a kinetics typical of 
hypoxia-selected LSC. In keeping with the results obtained with primary CML cells 
(Figure 28F), IM did not suppress LC2 repopulation. On the contrary, Compound X 
completely suppressed this repopulation. Interestingly, IM did not interfere with the 
effect of Compound X.  
Figure 30. Effects of Compound X and IM combined treatment on K562 cell line in 
hypoxia. Exponentially-growing K562 cells from routine cultures were replated in fresh 
medium at 3x105 cells/ml. Cultures were incubated in hypoxic LC1 in the absence (CTRL) 
or in the presence of 1µM Compound X or 1µM IM alone (X and IM, respectively) or in 
combination (X+IM). (A) Trypan blue-negative cells were counted at 2 days of LC1. 
Values represent mean ± S.E.M. of data obtained from 3 experiments. (B) Cells were 
transferred, after 7 days of LC1, into normoxic LC2 (established at 3x104 cells/ml) and 
trypan blue-negative cells were counted at the indicated times of incubation in LC2. 




Compound X reduced the colony-formation ability of murine or 
human primary CML cells. 
The effects of Compound X on the colony-formation ability in normoxia of 
murine and human primary CML cells were tested. Murine BM cells, obtained from 
Figure 31. Effects of Compound X treatment on the colony-formation ability of 
murine and human primary CML cells. (A, B and C) Murine BM cells were obtained 
from femurs and tibiae of three CML mice and plated in methylcellulose medium in the 
absence (Control) or in the presence of the indicated concentration of Compound X (X). 
The number of colonies was scored at the indicated times. (D and E) Human light-density 
BM mononuclear cells explanted from one CML patient were plated in methylcellulose 
medium in the absence (Control) or in the presence of the indicated concentrations of 
Imatinib (IM) or Compound X (X). Number of colonies (D) and representative pictures (E) 




femurs and tibiae of three CML mice, were incubated in methylcellulose medium in 
the absence or the presence of different concentrations of Compound X. At day 10 
of incubation, Compound X concentration-dependently inhibited colony formation, 
50 nM Compound X being the lowest significantly effective concentration (Figure 
31A and 31B). At day 17, interestingly, Compound X was effective at a lower 
concentration, 10 nM (Figure 31C). Thus, more immature colony-forming cells, 
generating later-appearing colonies, appeared more sensitive to Compound X 
than less mature colony-forming cells. 
Human light density BM mononuclear cells, obtained from one CML patient, 
were plated in methylcellulose medium in the absence or the presence of different 
concentrations of Compound X or IM and incubated in normoxia. The number of 
colonies was scored after 21 days (Figure 31D). Compound X 0.5µM or 1µM, as 
well as IM 1µM, significantly reduced the colony-formation ability of human CML 
cells. Although there was no difference in the number of colonies between cultures 
treated with 1µM Compound X or IM, colony morphology was quite different; 
indeed only small colonies were present in Compound X-treated cultures, while 
several large colonies were observed following IM treatment (Figure 31E). 
Compound X reduced the percentage and the number of LSK 
cells in the BM of CML mice. 
It has already been demonstrated that the in vivo genetic suppression of HIF-
1α causes an impairment of LSC function in CML mice [101]. Therefore, we 
examined whether inhibition of HIF-1α by Compound X also suppressed LSC in 
vivo using a CML mouse model. BM cells from 5-FU-treated mice were retrovirally 
transduced with BCR/ABL-GFP and transplanted into lethally irradiated recipient 
mice. One week after the Bone Marrow Transplantation (BMT), mice were treated 
daily with Compound X (2mg/kg) or placebo (control group). After two weeks of 
treatment, mice were sacrificed and BM was analyzed by FACS. 
Compound X did not affect the percentage of leukaemia cells (GFP+) in BM. 
Interestingly, no toxic effects of Compound X was observed on the percentage of 
non-leukaemia cells (GFP-) (Figure 32A). 
It has been demonstrated that the Lineage-Sca-1+c-kit+ (LSK) subset 
functions as LSC in CML, i.e. capable to induce CML in recipient mice [24]. The 
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effects of Compound X on LSK cells are shown in Figure 32B and 32C. 
Compound X significantly reduced the number and the percentage of LSK cells. 
To exclude toxic effects of Compound X on non-leukaemia LSK cells, BM 
cells from 5-FU-treated mice were retrovirally-transduced with GFP alone and 
transplanted into lethally-irradiated recipient mice, which were treated as indicated 
above. Compound X did not affect the total number or the percentage of non-
leukaemia GFP+ LSK cells (Figure 32D and 32E). 
  
Figure 32. Effects of Compound X treatment on the percentage and the number of 
LSK in BM of CML mice. BM cells from 5-FU-treated mice were retrovirally transduced 
with BCR/Abl-GFP (A, B and C) or GFP alone (D and E) and transplanted into lethally 
irradiated recipient mice. One week after BMT, mice were treated daily with 2mg/kg 
Compound X (X) or placebo (CTRL). After two weeks of treatment, mice were sacrificed 
and BM was analyzed by FACS. (A) Percentage of non-leukaemia (GFP-) or leukaemia 
(GFP+) cells in BM of CML mice. Percentage (B) and number (C) of GFP+LSK in BM of 





CML is a stem cell-driven disorder which is treated with impressive efficacy 
with TKi. Although TKi are unable in most cases to prevent the relapse, inducing a 
state of MDR, apparently due to the persistence of LSC. LSC survival in vivo most 
likely occurs, independently of BCR/Abl kinase activity, within the hypoxic 
environment of stem cell niches. HIF-1α is a key regulator of cell adaptation to 
hypoxia and its role in the maintenance of HSC and LSC has already been 
demonstrated [101].  
In this study, we wanted to evaluate the effects of HIF-1α pharmacological 
inhibition on the maintenance of LPC and LSC of CML. We compared three 
different putative HIF-1α inhibitors, identifying Compound X as a very effective 
inhibitor of CML cell survival and growth in hypoxia. Compound X also inhibited 
the colony-formation ability of primary human and murine CML cells. It was 
interesting to compare this effect with that of IM. There was no difference between 
Compound X and IM as for their effect on colony number. However, in Compound 
X-treated cultures, only small colonies were present, while some large colonies 
were detected in the presence of IM.  
Compound X, but not IM, suppressed LSC maintenance in hypoxia. These 
results were obtained with either CML cell lines or primary cells explanted from 
CML patients. According to these results, Compound X appeared suitable to be 
used alone to suppress MRD as well as CML cell bulk. However, TKi represent a 
consolidate standard for CML therapy, as they are extremely effective in inducing 
remission. Thus, we had to take into consideration also the possibility of a 
simultaneous or sequential use of Compound X with TKi, where Compound X is 
directed to target LSC specifically. In this scenario, we decided to test the effects 
of the simultaneous combination of Compound X with TKi, thinking that such a 
protocol better approaches a potential clinical setting. Therefore, it appeared 
necessary to exclude antagonist effects of IM with respect to Compound X. We 
found that, in fact, the two drugs had an additive effect as far as the total number 
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of viable cells in hypoxic cultures is concerned. On the other hand, IM did not 
interfere with the detrimental effect of Compound X on LSC maintenance. These 
results pointed to the feasibility of a simultaneous combination of Compound X 
with TKi. 
Using a murine model of BCR/Abl-induced CML, we analyzed in vivo the 
effects of Compound X on the maintenance of the LSC-containing LSK cell subset. 
Compound X significantly reduced the number and the percentage of leukaemia 
LSK in the BM of mice compared to the placebo treatment. Interestingly, 
Compound X did not affect HSC maintenance, pointing to a good therapeutic 
index of the drug in discriminating leukaemic from normal haematopoietic cells. 
Taken together, these results indicated that TKi-resistant LSC are instead 
sensitive to HIF-1α inhibition by Compound X. On this basis, we propose the 
Compound X/TKi combination as a novel therapeutic approach targeting CML cell 
bulk to induce remission and, at the same time, LSC to prevent the onset of MRD. 
 
A paper containing the main results of this thesis is in preparation. Its 
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